

## cGAS/STING-DEPENDENT SENSING OF ENDOGENOUS RNA

Tina Schumann<sup>1</sup>, Santiago Costas Ramon<sup>1</sup>, Nadja Schubert<sup>1</sup>, Mohamad Aref Mayo<sup>1,2</sup>, Melanie Hega<sup>2</sup>, Servi-Remzi Ada<sup>1</sup>, Lukas Sydow<sup>1</sup>, Mona Hajikazemi<sup>3</sup>, Yan Ge<sup>1,4</sup>, Markus Badstübner<sup>1</sup>, Stefan Lienenklaus<sup>5</sup>, Barbara Utess<sup>1</sup>, Lina Muhandes<sup>1,2</sup>, Michael Haase<sup>6</sup>, Luise Müller<sup>1</sup>, Marc Schmitz<sup>1,7,8</sup>, Thomas Gramberg<sup>9</sup>, Nicolas Manel<sup>10</sup>, Thomas Zillinger<sup>2</sup>, Stefan Bauer<sup>11</sup>, Alexander Gerbault<sup>1</sup>, Katrin Paeschke<sup>2</sup>, Axel Roers<sup>1,4</sup>, and Rayk Behrendt<sup>1,2,\*</sup>

<sup>1</sup>*Institute for Immunology, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany*

<sup>2</sup>*Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany*

<sup>3</sup>*Clinic of Internal Medicine III, Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Bonn, Germany*

<sup>4</sup>*Institute for Immunology, University Hospital Heidelberg, Heidelberg, Germany*

<sup>5</sup>*Institute of Laboratory Animal Science, Hannover Medical School, Hannover, Germany*

<sup>6</sup>*Department of Pediatric Surgery, University Hospital Dresden, Dresden, Germany*

<sup>7</sup>*National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany*

<sup>8</sup>*German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany*

<sup>9</sup>*Institute of Clinical and Molecular Virology, Friedrich-Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany*

<sup>10</sup>*INSERM U932, Institut Curie, PSL Research University, 75005, Paris, France*

<sup>11</sup>*Institute for Immunology, Philipps-University Marburg, Marburg, Germany*

\*Correspondence should be addressed to R.B.

### Summary

Loss of the dNTPase and DNA repair enzyme SAMHD1 is associated with cancer and causes systemic autoimmunity. We show transformation-promoting spontaneous DNA damage and MDA5-driven but cGAS/STING-dependent chronic type I interferon production in SAMHD1-deficient mice.

27 **Abstract**

28 Defects in nucleic acid metabolizing enzymes lead to spontaneous but selective activation of either  
29 cGAS/STING or RIG-like receptor (RLR) signaling, causing a pathogenic type I interferon response and  
30 inflammatory diseases. In these pathophysiological conditions, cGAS-driven IFN production is linked to  
31 spontaneous DNA damage. Physiological, or tonic, IFN signaling on the other hand is essential to functionally  
32 prime nucleic acid sensing pathways. Here we show that low-level chronic DNA damage in mice lacking the  
33 Aicardi-Goutières syndrome gene *SAMHD1* reduced tumor-free survival when crossed to a p53-deficient, but  
34 not to DNA mismatch repair-deficient background. Increased DNA damage did not result in higher levels of type  
35 I interferon. Instead, we found that the chronic interferon response in *SAMHD1*-deficient mice was driven by  
36 the MDA5/MAVS pathway but required functional priming through the cGAS/STING pathway. Our work  
37 positions cGAS/STING upstream of tonic IFN signaling and highlights an important role of the pathway in  
38 physiological and pathophysiological innate immune priming.

## 39 Introduction

40 Intracellular recognition of nucleic acids is essential in antiviral and in anti-tumor immunity, but uncontrolled  
41 activation of this machinery in the context of severe viral infections and tissue damage can cause detrimental  
42 inflammation. The same potent and therefore dangerous response is initiated when cells fail to control  
43 emergence of endogenous nucleic acids in amounts that exceed normal physiological levels or that lack  
44 secondary modifications, which would prevent autoactivation of nucleic acid receptors such as the dsDNA  
45 sensor cGAS or the RIG-like dsRNA receptors (RLR) RIG-I, MDA5 and LGP2 (Ablasser and Hur, 2020). RIG-I  
46 senses blunt-end dsRNA based on the presence or absence of 5' modifications, while MDA5 requires dsRNA  
47 stem structures of so far unknown minimal length (Ablasser and Hur, 2020). The enzyme cGAS senses  
48 nucleosome-free dsDNA inside of cells and produces the second messenger 2'3'cGAMP, a direct ligand for the  
49 cyclic-di-nucleotide sensor STING (de Oliveira Mann and Hopfner, 2021). Nucleosome-free dsDNA has been  
50 shown to accumulate in cells after DNA damage and therefore DNA damage has been identified as a primary  
51 pathogenic event in an increasing number of sterile inflammatory conditions that are driven by cGAS/STING-  
52 dependent cytokine production (Crow and Stetson, 2021). Both, activated STING and MAVS, recruit the kinase  
53 TBK1 leading to downstream activation of type I interferon (IFN) and NF- $\kappa$ B responses. IFN in turn acts autocrine  
54 and paracrine to stimulate expression of primarily antiviral genes via the type I IFN receptor (IFNAR). In many,  
55 but not in all cell types, expression of several pattern recognition receptors, including cGAS and the RLRs is  
56 regulated via this positive-feedback loop and depends on tonic IFN signaling, which leads to severely reduced  
57 PRR levels in IFNAR-deficient cells compared to IFNAR-competent cells (Behrendt et al., 2013; Schaupp et al.,  
58 2020). This results in a broad antiviral immune-defect in mice (Cervantes-Barragán et al., 2009; Schaupp et al.,  
59 2020) and in humans with inborn errors of the IFN system (Zhang et al., 2020). How exactly tonic IFN signaling  
60 is established and how this impacts physiological and pathophysiological immune priming is an emerging topic.  
61 Aicardi-Goutières syndrome (AGS) is a monogenic systemic autoimmune disease that is associated with high  
62 levels IFN in peripheral blood and in cerebrospinal fluid (Rodero and Crow, 2016). Mutations in AGS genes lead  
63 to spontaneous but selective activation of either RIG-like-receptor or cGAS/STING signaling (Crow and Stetson,  
64 2021). The latter pathway has been implicated in the pathogenesis of AGS with underlying defects in the gene  
65 *SAMHD1* (AGS5) (Rice et al., 2009, 1; Maelfait et al., 2016; Daddacha et al., 2017; Coquel et al., 2018). *SAMHD1*  
66 has at least two different functions: It's an enzyme with deoxynucleoside triphosphate triphosphohydrolase  
67 (dNTPase) activity (Goldstone et al., 2011). Through this activity, *SAMHD1* limits the availability of dNTPs in  
68 resting cells, which hinders replication of pathogens like retroviruses that depend on cellular dNTP supply  
69 (Hrecka et al., 2011; Laguette et al., 2011). Furthermore, increased levels of *SAMHD1* in relapsed hematopoietic  
70 tumors have been shown to degrade nucleotide analogues thereby diminishing the efficacy of chemotherapy  
71 (Schneider et al., 2017; Herold et al., 2017). Moreover, *SAMHD1*-deficient tumor cells can be selectively killed  
72 through targeting the nucleotide metabolism (Davenne et al., 2020) making it an attractive anti-cancer drug  
73 target. A second function of *SAMHD1* is reflected by the recruitment of the enzyme to sites of DNA double  
74 strand breaks (DSB) and to stalled replication forks. There, it interacts with the endonuclease CtIP and with the  
75 MRN complex to facilitate end resection in preparation for DSB repair by homologous recombination and to  
76 enable fork-restart (Daddacha et al., 2017; Coquel et al., 2018). The latter function does not require dNTPase  
77 activity and is mediated by the C-terminal region of *SAMHD1*. Failure in recruiting the DNA repair machinery by  
78 *SAMHD1* results in spontaneous DNA damage and in the release of self-DNA that has been suggested to  
79 activate cGAS (Daddacha et al., 2017; Coquel et al., 2018). In agreement with its functions in DNA repair,  
80 *SAMHD1*-deficient patient fibroblasts showed a spontaneous transcriptional signature of interferon-stimulated  
81 genes (ISGs) and increased numbers of DNA double strand breaks (Kretschmer et al., 2015). The latter caused a  
82 chronic activation of the p53 pathway and senescence (Kretschmer et al., 2015). Impaired DNA repair pre-  
83 disposes to malignant transformation and consequently, mutations in *SAMHD1* have been identified in many  
84 different tumors (Clifford et al., 2014; Rentoft et al., 2016). However, mutations found in cancer cells scatter  
85 across the whole *SAMHD1* gene (reviewed by (Mauney and Hollis, 2018) and do not allow for general conclusion  
86 about a definitive mechanism that could explain how the protein prevents malignant transformation. Here, two  
87 scenarios seem plausible: Loss of *SAMHD1* dNTPase activity could affect the composition of cellular dNTP  
88 pools, which has a direct effect on the fidelity of replicative polymerases and could cause a mutator phenotype.

89 This has been widely studied in cancers originating from de-regulation of the ribonucleotide reductase complex  
90 (Aye et al., 2015). On the other hand, loss of SAMHD1-mediated DNA repair activity could cause increased  
91 numbers of DSBs and delay their repair, which might promote the selection of cell clones that inactivated cell  
92 cycle checkpoints to overcome this block. However, none of these scenarios have been experimentally  
93 addressed using in vivo models.

94 In addition to these established functions of SAMHD1, one group reported an exonuclease activity of the  
95 protein (Choi et al., 2015; Ryoo et al., 2014, 2016). However, RNase activity of SAMHD1 was not reproduced by  
96 other studies (Seamon et al., 2015; Antonucci et al., 2016; Bloch et al., 2017; Yu et al., 2021), including our own  
97 (Wittmann et al., 2015). Therefore, if and how SAMHD1 regulates RNA metabolism in cells, remains to be fully  
98 elucidated.

99 In contrast to patients, loss of SAMHD1 in mice caused a mild activation of the type I IFN system but no systemic  
100 autoimmunity (Behrendt et al., 2013; Rehwinkel et al., 2013; Thientosapol et al., 2018). The IFN response was  
101 shown to be mediated via the cGAS/STING pathway (Maelfait et al., 2016). Furthermore, as opposed to studies  
102 in human cells lacking SAMHD1, no spontaneous DNA damage and no increased frequency of spontaneous  
103 tumors have been described in three independently generated SAMHD1-deficient mouse strains (Behrendt et  
104 al., 2013; Rehwinkel et al., 2013; Thientosapol et al., 2018). The lack of detectable DNA damage but the presence  
105 of a spontaneous IFN response in these mutant mice is an unresolved incoherence with the current  
106 understanding of how IFN is induced in SAMHD1-deficient cells.

107 Here we show low-level chronic DNA damage in SAMHD1-deficient mice that is detected by the p53 pathway.  
108 We found that inactivation of SAMHD1 in p53-deficient mice, but not in mice with defective DNA mismatch  
109 repair, reduced the tumor-free survival. Surprisingly, increased DNA damage did not amplify the spontaneous  
110 IFN response in SAMHD1-deficient mice. In contrast, we found that IFN is induced via the RNA sensor MDA5.  
111 Using SAMHD1-deficient mice as a model, we show that innate immune sensing of endogenous RNA through  
112 the RLR pathway requires functional priming via the cGAS/STING pathway.

113

## 114 **Results**

### 115 **1. Low level chronic DNA damage in SAMHD1-deficient mice**

116 We and others previously reported a mild spontaneous IFN response in *Samhd1* knockout mice, which was  
117 dependent on the cGAS/STING pathway, suggesting that it was triggered by endogenous DNA (Behrendt et al.,  
118 2013; Maelfait et al., 2016). So far, however, there were no reports about spontaneous DNA damage in  
119 SAMHD1-deficient mice, which led us to ask if IFN in these mice is induced by an alternative mechanism to the  
120 human or if evidence of spontaneous DNA damage has been overlooked. Indeed, gene set enrichment analysis  
121 (GSEA) of whole transcriptome data from peritoneal macrophages revealed that only two types of pathways,  
122 reflecting an ongoing inflammatory response, including type I IFN, and replication stress were enriched in  
123 SAMHD1-deficient macrophages over control macrophages (Fig. 1A). This is in line with previous reports about  
124 human cells and suggests that also mouse SAMHD1 acts on stalled replication forks and in DNA repair  
125 (Daddacha et al., 2017; Coquel et al., 2018). Furthermore, nuclei of primary SAMHD1-deficient MEFs showed  
126 slightly elevated levels of  $\gamma$ H2AX, a genuine marker for DNA strand breaks, when compared to littermate control  
127 MEFs (Fig 1B). Of note, in our hands this difference equilibrated after passage four and was no longer detectable  
128 in clones that overcame replicative senescence (not shown). DNA damage in erythroid precursors results in DNA  
129 double strand breaks and the rapid emergence of micronucleated reticulocytes followed by an increase of  
130 micronucleated erythrocytes, which can act as a short and long-term memory of genotoxic insults, respectively.  
131 After sub-lethal whole body irradiation, frequencies of micronucleated reticulocytes were increased by 4-fold in  
132 irradiated vs. non-irradiated *Samhd1*<sup>+/+</sup> mice (Fig. 1C). This increase was doubled in *Samhd1*<sup>Δ/Δ</sup> mice, indicating  
133 higher susceptibility of SAMHD1-deficient mice to genotoxic stress (Fig. 1C). Next, we compared the steady-  
134 state frequencies of micronucleated erythrocytes in the peripheral blood of several SAMHD1-deficient mouse  
135 strains in our colony. Compared to the respective SAMHD1-proficient control of the same mutant strain,  
136 animals that lacked SAMHD1 consistently showed higher frequencies of micronucleated erythrocytes in  
137 peripheral blood, indicative of low-level chronic spontaneous DNA damage in these mice (Fig. 1D). Taken

138 together, our results suggest that in SAMHD1-deficient mice genome replication and DNA repair are impaired  
139 resulting in low levels of chronic DNA damage.

140

## 141 **2. Loss of SAMHD1 reduces tumor-free survival of mice lacking p53, but not of mice with defective DNA** 142 **mismatch repair**

143 Next, we asked why SAMHD1-deficient mice do not develop increased frequencies of spontaneous tumors  
144 although they showed spontaneous DNA damage in various cell types. Patient fibroblasts lacking SAMHD1  
145 activate the p53 pathway in response to spontaneous DNA damage (Kretschmer et al., 2015). We reasoned that  
146 the low-level DNA damage in *Samhd1<sup>ΔΔ</sup>* mice can be kept in check by p53-mediated damage responses and  
147 that inactivation of the p53 pathway might reveal how loss of SAMHD1 impacts genome stability in vivo. To  
148 address this question, we crossed SAMHD1-deficient mice to *Trp53<sup>-/-</sup>* mice, which predominantly develop  
149 spontaneous thymic lymphoma (Jacks et al., 1994). In our colony, *Trp53<sup>-/-</sup>* mice showed a mean tumor-free  
150 survival of 28 weeks, which was reduced to 18 weeks in *Samhd1<sup>ΔΔ</sup>Trp53<sup>-/-</sup>* mice (Fig. 2A). In a cohort of *Trp53<sup>-/-</sup>*  
151 mice sacrificed at 12 weeks of age we found slightly enlarged thymi compared to control mice. At the same age,  
152 *Samhd1<sup>ΔΔ</sup>Trp53<sup>-/-</sup>* thymi were already significantly larger than thymi of the *Trp53<sup>-/-</sup>* group (Fig. 2B).  
153 Histopathologic examination of thymic sections from the same cohort revealed that in 5 out of 6  
154 *Samhd1<sup>ΔΔ</sup>Trp53<sup>-/-</sup>* mice the disease had already progressed to thymic lymphoma, while at that time point no  
155 lymphoma cells were identified in thymus sections from *Trp53<sup>-/-</sup>* mice (Fig. 2C & D). Subsequent  
156 immunophenotypic analysis by multicolor immunohistochemistry demonstrated that CD4<sup>+</sup>CD8<sup>-</sup> double  
157 negative CD3<sup>+</sup> T cells were the dominant population in thymi of *Samhd1<sup>ΔΔ</sup>Trp53<sup>-/-</sup>* (Fig. 2E and S1) mice, and this  
158 population emerged in *Samhd1<sup>ΔΔ</sup>Trp53<sup>-/-</sup>* mice before 12 weeks of age most evident in the CD25<sup>-</sup> T cell subsets  
159 DN1 (Fig. 2F) and DN4 (Fig. S2A). Longitudinal quantification of T cell development further supported that the  
160 disease of *Trp53<sup>-/-</sup>* mice develops faster but not qualitatively different in the absence of SAMHD1 (Fig. S2A). PCR  
161 on total thymus DNA amplifying specific recombination events in the TCRβ genes (Martins et al., 2014)  
162 demonstrated T cell bi- or oligoclonality indicative of thymic T cell lymphoma (Fig. S2B). Our data thus show  
163 that additional loss of SAMHD1 accelerated malignant transformation in *Trp53<sup>-/-</sup>* mice most likely by enhancing  
164 DNA damage.

165

166 We then asked if the altered nucleotide metabolism might contribute to malignant transformation in  
167 *Samhd1<sup>ΔΔ</sup>Trp53<sup>-/-</sup>* mice. Due to altered dNTP levels, tumor cells lacking SAMHD1 can be selectively killed by 2'-  
168 deoxy-guanosin (dG) (Davenne et al., 2020). Indeed, we observed that immortalized *Samhd1<sup>ΔΔ</sup>Trp53<sup>-/-</sup>* but not  
169 *Trp53<sup>-/-</sup>* thymic fibroblasts were hyper-sensitive to dG treatment, confirming that aberrant nucleotide  
170 metabolism caused by deficiency for SAMHD1 in cancer cells is an attractive drug target (Fig. 2G). Imbalanced  
171 dNTP levels decrease the fidelity of replicative polymerases and increase numbers of DNA mismatch mutations  
172 (Aye et al., 2015). In such a scenario, loss of SAMHD1 would be expected to reduce the tumor-free survival of  
173 DNA mismatch repair (MMR)-deficient mice. To test this hypothesis, we crossed *Samhd1<sup>ΔΔ</sup>* mice to *Pms2<sup>-/-</sup>*  
174 mice, which lack functional MMR and develop spontaneous lymphoma (Baker et al., 1995). Surprisingly, and in  
175 contrast to our observations in *Trp53<sup>-/-</sup>* mice, loss of SAMHD1 did not significantly reduce the tumor-free survival  
176 of *Pms2<sup>-/-</sup>* mice (Fig 2H; 50% mean survival *Samhd1<sup>ΔΔ</sup>Pms2<sup>-/-</sup>* 47 weeks, *Pms2<sup>-/-</sup>* 49 weeks, log-rank p=0.4052).  
177 This suggested that loss of SAMHD1 in mice is not associated with a strong mutator phenotype and that  
178 accelerated transformation seen in *Trp53<sup>-/-</sup>* mice lacking SAMHD1 is mainly driven by other forms of DNA  
179 damage.

180 To better understand the molecular events leading to reduced survival of *Samhd1<sup>ΔΔ</sup>Trp53<sup>-/-</sup>* mice, we quantified  
181 the frequency of micronucleated erythrocytes in peripheral blood and found higher frequencies in  
182 *Samhd1<sup>ΔΔ</sup>Trp53<sup>-/-</sup>* mice compared with *Trp53<sup>-/-</sup>* mice (Fig. 2I). In line with these observations, we detected a  
183 higher γH2AX signal in *Samhd1<sup>ΔΔ</sup>Trp53<sup>-/-</sup>* versus *Trp53<sup>-/-</sup>* primary MEFs further supporting overall increased  
184 spontaneous DNA damage inflicted by additional loss of SAMHD1 in *SAMHD1<sup>ΔΔ</sup>* in *Trp53<sup>-/-</sup>* mice (Fig. 2J).  
185 Independently of its role as a dNTPase, SAMHD1 recruits the MRN complex to promote homologous  
186 recombination at sites of DSBs and to re-start stalled replication forks. Telomeres consist of repetitive DNA

187 sequences and form R-loop structures, both of which can lead to replication fork stalling. In cells with a defective  
188 shelterin complex, which protects telomeres from being recognized by the DNA repair machinery, SAMHD1 has  
189 been shown to prevent telomere breakage and the formation of extrachromosomal ("outsider") telomere  
190 signals (Majerska et al., 2018). Quantification of telomere integrity in transformed *Samhd1<sup>ΔΔ</sup>Trp53<sup>-/-</sup>* versus  
191 *Trp53<sup>-/-</sup>* thymic fibroblasts by FISH revealed higher frequencies of chromosomes displaying single or double  
192 telomere loss or the characteristic outsider telomere signals (Fig. 2K). Our data suggests that loss of SAMHD1  
193 in mice inflicts spontaneous DNA damage that is counteracted by a p53 response and in the absence of p53  
194 accelerates tumor development. Accelerated transformation is more likely to be the result of increased  
195 numbers of DSBs in "difficult-to-replicate" regions, like telomeres, rather than being caused by a pronounced  
196 mutator phenotype.

### 198 3. Additional DNA damage does not amplify the spontaneous IFN response in SAMHD1-deficient mice

199 Cancer cell-intrinsic activation of the cGAS/STING pathway restricts tumor growth. This can be achieved by  
200 exogenous stimulation using synthetic ligands (reviewed in (Demaria et al., 2019)) or by promoting  
201 unphysiological accumulation of endogenous nucleic acids (Vanpouille-Box et al., 2019; Ishizuka et al., 2019).  
202 To investigate the role of endogenous DNA sensing in controlling tumor development in *Samhd1<sup>ΔΔ</sup>Trp53<sup>-/-</sup>* mice,  
203 we crossed this mouse line to a STING-deficient background (Goldenticket mouse, *Sting1<sup>GT/GT</sup>*). Loss of STING  
204 had no effect on tumor-free survival of *Samhd1<sup>ΔΔ</sup>Trp53<sup>-/-</sup>* mice (Fig. 3A) suggesting that STING signaling is not  
205 crucial in controlling the growth of *Samhd1<sup>ΔΔ</sup>Trp53<sup>-/-</sup>*-deficient tumors. We and others previously reported that  
206 loss of p53 increased DNA damage and potentiated the spontaneous cGAS/STING-dependent IFN response in  
207 mice (Hiller et al., 2018) and in iPSCs (Giordano et al., 2022) with a defect in the essential DNA repair enzyme  
208 RNaseH2, strongly implicating genome damage in the generation of immune stimulatory DNA in this model.  
209 To better understand the lack of an effect of STING-deficiency in our *Samhd1<sup>ΔΔ</sup>Trp53<sup>-/-</sup>* mouse model, we  
210 quantified the spontaneous activation of the type I IFN system. We observed increased levels of the surface ISG  
211 Sca-1 on peripheral blood lymphocytes (Fig. 3B) and increased transcription of several ISGs in peripheral blood  
212 of *Samhd1<sup>ΔΔ</sup>* vs. *Samhd1<sup>+/+</sup>* control mice (Fig. 3C). However, this response was not further increased by  
213 additional loss of p53 (Fig. 3B & C). We made similar observations in bone marrow-derived macrophages from  
214 *Samhd1<sup>ΔΔ</sup>Trp53<sup>-/-</sup>* and control mice (Fig. 3D). Of note, like in the p53 model, ISG transcription was similar  
215 between *Samhd1<sup>ΔΔ</sup>* and *Samhd1<sup>ΔΔ</sup> Pms2<sup>-/-</sup>* mice (Fig. 3E).

216 In contrast to our previous observations in RNaseH2-deficient mice (Hiller et al., 2018), and despite higher levels  
217 of spontaneous DNA damage upon loss of SAMHD1 in p53-deficient mice (Fig. 2), this did not result in a stronger  
218 activation of the IFN system rendering STING signaling irrelevant in the control of tumor growth. We conclude  
219 that the p53-dependent DNA damage response does not function to prevent the generation of IFN-inducing  
220 endogenous nucleic acids in SAMHD1-deficient cells.

221

### 222 4. MDA5 drives IFN production in a cGAS/STING-dependent manner in *Samhd1<sup>ΔΔ</sup>* mice

223 Our observation that increased DNA damage did not boost the IFN response in SAMHD1-deficient mice led us  
224 to investigate the exact role of cGAS/STING signaling in this model. To address whether STING signaling is  
225 important in SAMHD1-deficient mice, we treated *Samhd1<sup>ΔΔ</sup>* mice for two weeks with 10 mg/kg of the STING  
226 antagonist H-151 (Haag et al., 2018). Pharmacologic inhibition of STING was able to reduce the transcription of  
227 ISGs in peripheral blood, demonstrating that STING is required for spontaneous IFN production in SAMHD1-  
228 deficient mice and that it represents a valuable therapeutic target to treat inflammatory conditions ensuing  
229 from defects in SAMHD1 (Fig. 3A). Until now, spontaneous IFN production caused by bi-allelic mutations in  
230 any of the AGS-related genes could be explained by activation of either the cGAS/STING pathway or the RLR  
231 pathway. In order to confirm that loss of SAMHD1 selectively activated the cGAS/STING pathway, we turned to  
232 a genetic approach to directly compare the relevance of intracellular DNA and RNA sensing in SAMHD1-  
233 deficient mice. As expected from our data with the STING inhibitor, knockout of *Sting1* completely blunted the  
234 ISG response in *Samhd1<sup>ΔΔ</sup>* mice (Fig. 4A & B). To our surprise, also loss of MAVS abrogated the ISG response in  
235 SAMHD1-deficient peritoneal macrophages. This suggested that in contrast to mutations in other AGS  
236 enzymes, both, intact STING and MAVS signaling are required for the spontaneous IFN production in SAMHD1-

237 deficient mice (Fig. 4A & B). Next, we asked if the nucleic acid sensors upstream of MAVS and STING were  
238 chronically activated in SAMHD1-deficient cells, or if there was a direct cross-talk between the two pathways at  
239 the level of STING and MAVS. To this end, we used post-replicative senescence *Samhd1<sup>ΔΔ</sup>* MEFs that retained  
240 a spontaneous ISG response, which could be rescued by lentiviral expression of murine SAMHD1 (Fig. S3B). In  
241 these MEFs we inactivated cGAS, RIG-I (*Ddx58*) and MDA5 (*Ifih1*) using CRISPR/Cas9 (Fig. S3C). As observed  
242 before, knockout of *cGas* completely blunted the transcription of several ISGs in SAMHD1-deficient cells (Fig.  
243 4C). For the RIG-like receptors, only loss of MDA5 but not of RIG-I was able to reduce the mRNA levels of the  
244 ISGs tested (Fig. 4C). To further substantiate our finding that the spontaneous ISG response is indeed MDA5-  
245 dependent, we crossed *Samhd1<sup>ΔΔ</sup>* mice to *Ifih1<sup>-/-</sup>* mice and analyzed the transcriptome of peritoneal  
246 macrophages. Like in previous experiments, inflammatory pathways and pathways indicating DNA replication  
247 stress were enriched in peritoneal macrophages from *Samhd1<sup>ΔΔ</sup>* mice compared with control mice (Fig. 4D &  
248 4E). In contrast, in peritoneal macrophages from *Samhd1<sup>ΔΔ</sup> Ifih1<sup>-/-</sup>* mice only pathways related to DNA  
249 replication and cell cycle progression remained enriched, when compared to control macrophages (Fig. 4D &  
250 4E). The absence of upregulated inflammatory pathways in *Samhd1<sup>ΔΔ</sup> Ifih1<sup>-/-</sup>* mice indicated that MDA5 is  
251 chronically activated in SAMHD1-deficient mice and suggested the presence of endogenous immune-  
252 stimulatory dsRNA.

253 We were still puzzled by the requirement for cGAS in this system that was independently observed by us and by  
254 other groups (Maelfait et al., 2016; Coquel et al., 2018). Our transcriptomes of STING-deficient peritoneal  
255 macrophages (Fig. 4B) and as well qPCR results of cGAS-deficient MEFs (Fig. 4C) showed that ISG-expression  
256 in the mutant cells is below the levels found in cGAS/STING-competent control cells. This suggested that cGAS  
257 primes the antiviral immune system, most likely by its sporadic activation in response to endogenous DNA. To  
258 address the relevance of cGAS-mediated immune priming in the absence of SAMHD1, we generated SAMHD1-  
259 deficient mice that express GFP-tagged cGAS (Gentili et al., 2019) from a hypomorphic allele reducing the cGAS  
260 protein level to around 20% compared to that in WT mice (Fig. S3D). Whole transcriptome sequencing of  
261 BMDMs from *Samhd1<sup>ΔΔ</sup>GFP-cGas<sup>K1/K1</sup>* and control mice demonstrated reduced expression of ISGs including  
262 several pattern recognition receptors and among these RIG-I (*Ddx58*) and MDA5 (*Ifih1*) (Fig. 4F).  
263 Haploinsufficiency for *cGas* rescues mice lacking the DNase *Trex1* from lethal autoimmunity (Gao et al., 2015;  
264 Gray et al., 2015), suggesting that even in terminally sick *Trex1<sup>-/-</sup>* mice, the amount of cGAS ligands is only  
265 slightly above the threshold of tolerance. In contrast to *Trex1<sup>-/-</sup>* mice, the spontaneous IFN response in SAMHD1-  
266 deficient mice is very weak as illustrated by the lack of a spontaneous signal in *Samhd1<sup>ΔΔ</sup> Ifnβ-LUC* reporter  
267 mice (Fig. S3E) rendering it even more sensitive to fluctuations in the cGAS protein level. As reported for  
268 reduced levels of cGAS, reduced levels of RIG-I and MDA5 might de-sensitize the intracellular RNA sensing  
269 pathways. To test if the sensitivity of the RLR pathway is controlled by cGAS, we knocked out *cGas* in LL171 ISG-  
270 luciferase reporter cells. As expected, no luciferase activity was detected after transfection of plasmid DNA.  
271 However, also the response to transfected poly I:C was almost completely blunted (Fig. 4G). Next, we isolated  
272 BMDMs from *cGas<sup>-/-</sup>* and littermate control mice and transfected them with increasing amounts of  
273 5' triphosphate dsRNA to stimulate a RIG-I response. As observed for the poly I:C response, the same amounts  
274 of RIG-I ligand only induced lower IFN levels in the supernatant of *cGas<sup>-/-</sup>* BMDMs compared with controls (Fig.  
275 4H). Taken together, our results suggest that cGAS keeps expression of PRRs at functional levels, which enables  
276 sensing of endogenous dsRNA by MDA5 in cells lacking SAMHD1.

## 277 278 Discussion

279 We showed that loss of SAMHD1 in mice leads to a DNA replication defect, which causes DNA damage that is  
280 counteracted by activation of a p53 response. Loss of SAMHD1 in tumor cells exacerbates DNA damage in  
281 difficult-to-replicate regions like telomeres, which might contribute to accelerated malignant transformation  
282 when DNA repair pathways are impaired. Our observations of increased telomere damage in tumor cells lacking  
283 SAMHD1 are in line with previous reports of SAMHD1 being part of the telomere proteome (Majerska et al.,  
284 2018; Lin et al., 2021) and with increased frequencies of R-loop structures in SAMHD1-deficient cells (Park et al.,  
285 2021). Contrary to our observations in the p53-deficient tumor model, loss of SAMHD1 in MMR-deficient mice  
286 had no effect on tumor-free survival. This was unexpected as earlier reports demonstrated that even *Samhd1<sup>+/-</sup>*

287 mice had elevated dNTP levels and mutations in the ribonucleotide reductase complex cause a cancerogenic  
288 mutator phenotype as a results of altered dNTP levels (Rentoft et al., 2016; Aye et al., 2015). *Samhd1<sup>ΔA</sup>* mice  
289 lack dNTPase and DNA repair activity suggesting that loss of neither activity leads to significant DNA damage  
290 that would be detected by the MMR machinery in vivo. Hence, we conclude that loss of SAMHD1 in mice does  
291 not cause a strong mutator phenotype.

292 Activation of the innate immune response has been shown to efficiently control tumor growth and various  
293 means for targeted activation of intracellular nucleic acid sensing pathways are currently developed to boost  
294 anti-tumor immunity (Demaria et al., 2019). As opposed to exogenous stimulation of the pathway, STING had  
295 no role in regulating the tumor-free survival of *Samhd1<sup>ΔA</sup>Trp53<sup>-/-</sup>* mice suggesting that endogenous DNA  
296 damage in p53-deficient tumors only weakly, if at all, activates STING. The relevance of our observation is  
297 illustrated by the fact that every other tumor in humans carries homozygous inactivation of the p53 gene (Baugh  
298 et al., 2018) and supported by a report showing that cGAS, but not STING protects from malignant  
299 transformation in a chemical-induced model of colon cancer (Hu et al., 2021). In order to fully understand the  
300 differential roles of cGAS and STING in controlling tumor growth, dissecting their multifaceted roles in  
301 regulating anti-tumor immunity and in controlling DNA damage will be instrumental.

302 We recently reported evidence that the IFN response in *Trex1<sup>-/-</sup>* mice is linked to DNA replication (Schubert et  
303 al., 2022) and similar findings have been reported for *SAMHD1<sup>-/-</sup>* cells (Coquel et al., 2018). In both models, loss  
304 of p53 did not amplify the IFN response, while such p53-dependent amplification was observed in cells lacking  
305 RNaseH2, in which chromatin fragments activate cGAS (Hiller et al., 2018; Mackenzie et al., 2017; Giordano et  
306 al., 2022). This points to a differential involvement of the p53 pathway in the generation of immune stimulatory  
307 DNA as a result of DNA replication in cells lacking TREX1 or SAMHD1 compared with post-replicative DNA  
308 damage found in RNaseH2-deficient cells. Although in SAMHD1-deficient cells accumulation of ssDNA species  
309 and concomitant activation of cGAS has been reported, it still remains unclear whether these oligonucleotides  
310 represent direct ligands for the DNA sensor, which, under physiological conditions, is known to nucleate only in  
311 the presence of unprotected long dsDNA (Andreeva et al., 2017; Du and Chen, 2018). Thus, it remains possible  
312 that in SAMHD1-deficient cells cGAS activation had a different culprit. Furthermore, our results challenge a role  
313 of pathogenic DNA sensing in SAMHD1-deficient mice as inactivation of RLR sensing in SAMHD1-deficient but  
314 cGAS/STING-competent cells was sufficient to blunt the spontaneous IFN response. This cannot be explained  
315 by a lack of RLR-mediated immune priming because ISGs levels in MAVS-deficient mice were similar to that of  
316 wild type mice, while in the absence of STING they were below levels found in wild type mice (Fig. 4B). ISG  
317 transcription was also lower in *Samhd1<sup>ΔA</sup>Sting1<sup>GT/GT</sup>* when compared to *Samhd1<sup>ΔA</sup>Mavs<sup>-/-</sup>* mice (Fig. S3F).

318 We previously observed that pDCs are the main producers of tonic IFN in mice (Peschke et al., 2016), which was  
319 later shown to be induced in response to commensal bacteria activating TLR and MAVS signaling pathways  
320 (Schaupp et al., 2020). In the skin, microbiota induced de-repression of endogenous retroelements and a  
321 cGAS/STING-dependent IFN response, but in this study MAVS signaling was not investigated (Lima-Junior et  
322 al., 2021). Interestingly, in human macrophages phagocytosed gut commensal bacteria evoked an IFN  
323 response, which was co-dependent on STING and MAVS expression (Gutierrez-Merino et al., 2020), suggesting  
324 that innate immune priming in response to low-level chronic stimuli can be driven by innate sensing of  
325 endogenous DNA and RNA. Our transcriptome data indicated that in mouse peritoneal macrophages, in  
326 primary BMDMs and in the murine fibroblasts cell line LL171 the cGAS/STING pathway establishes tonic IFN  
327 signaling and baseline expression of antiviral genes, including RLRs. This places cGAS/STING signaling  
328 upstream of RLR sensing in these cell types, because the absence of this pathway leads to impaired cytoplasmic  
329 RNA sensing (Fig. 4 G & 4H). Similar findings have been reported in the context of RNA virus infections  
330 (Schoggins et al., 2014; Parker et al., 2018). As the IFN response in SAMHD1-deficient mice is weak, we propose  
331 that loss of cGAS/STING signaling in cells lacking SAMHD1 de-sensitizes the RLR pathways and increases  
332 tolerance against RNA ligands, thereby preventing spontaneous induction of IFN despite the presence of an  
333 endogenous MDA5 ligand. To this end, dsRNA originating from endogenous retroelements has been shown to  
334 activate MDA5 in cells lacking the AGS gene ADAR1 (Ahmad et al., 2018) and after DNA damage induced by  
335 chemotherapy (Clapes et al., 2021). De-repression of endogenous retroelements is not only a physiological  
336 response (Lima-Junior et al., 2021; Young et al., 2012; Yu et al., 2012) but it is also a general stress-response



337 (Simon et al., 2019; De Cecco et al., 2019), and SAMHD1-deficient cells display signs of replication stress  
338 including spontaneous DNA damage as shown here and previously by other groups (Daddacha et al., 2017;  
339 Coquel et al., 2018). Therefore, it is tempting to speculate that the stress response alone is sufficient to promote  
340 aberrant transcription and processing of endogenous RNA from, but not limited to, the vast numbers of  
341 retroelement loci, which might lead to autorecognition by RNA sensors in SAMHD1-deficient cells.

342 Taken together, our work suggests that in SAMHD1-deficient cells endogenous dsRNA represents the primary  
343 nucleic acid ligand that drives IFN production and implicates an important role of the cGAS/STING pathway in  
344 physiological and pathophysiological innate immune priming.

345

## 346 **Material and Methods**

### 347 Mice

348 *Samhd1<sup>Δ/Δ</sup>* (Behrendt et al., 2013), *cGas<sup>-/-</sup>* (Schoggins et al., 2014), *Mavs<sup>-/-</sup>* (Michallet et al., 2008), *Sting1<sup>GT/GT</sup>*  
349 (Sauer et al., 2011), *Ifih1<sup>-/-</sup>* (Gitlin et al., 2006), *Trp53<sup>-/-</sup>* (Jacks et al., 1994), *Pms2<sup>-/-</sup>* (Baker et al., 1995), *Trex1<sup>-/-</sup>*  
350 (Morita et al., 2004), *ΔβLUC<sup>KI/KI</sup>* (Lienenklaus et al., 2009) and *GFP-cGas<sup>KI/KI</sup>* (Gentili et al., 2019) mice were  
351 described previously. *Trp53<sup>-/-</sup>* (#002101) and *Pms2<sup>-/-</sup>* (#010945) were purchased from The Jackson Laboratory.  
352 Mice were housed under specific pathogen-free conditions at the Experimental Center of the University of  
353 Technology Dresden. All animal experiments were done according to institutional guidelines on animal welfare  
354 and were approved by the Landesdirektion Sachsen (11-1/2010-33, 24-1/2013-12, 24/2017; 88/2017).

355

### 356 Mouse embryonic fibroblasts

357 MEFs were generated by standard procedures. In brief, E11.5 mouse embryos were dissected and decapitated.  
358 After removal of internal organs, tissue was cut into small pieces, digested with 1x trypsin (0.25 %, Invitrogen)  
359 for 30 min at 37°C and disaggregated by pipetting. The cell suspension was cultured in DMEM (Gibco)  
360 supplemented with 10 % heat-inactivated fetal calf serum, 100 U/ml Penicillin, 100 mg/ml Streptomycin, 1x non-  
361 nonessential amino acids (all Biochrom) and 100 μM β-mercaptoethanol (Gibco). After 24 h, non-digested  
362 tissue aggregates were removed and the cells were kept cultivated in complete DMEM medium at 37°C and 5 %  
363 CO<sub>2</sub> under atmospheric oxygen.

364

### 365 Thymic fibroblasts

366 Thymi were homogenized and passed through a 40 μm cell filter. The single cell suspension was cultured in  
367 RPMI 1640 medium supplemented with 10 % heat-inactivated fetal calf serum, 100 U/ml Penicillin, 100 mg/ml  
368 Streptomycin, 1 mM sodium pyruvate and 2 mM L-Alanyl L-glutamine (all Biochrom). Surviving cells were kept  
369 cultivated in complete RPMI 1640 medium at 37°C and 5 % CO<sub>2</sub> under atmospheric oxygen.

370

### 371 In Vitro Differentiation of BMDMs

372 Bone marrow cells were cultured over night in RPMI 1640 medium supplemented with 10 % heat-inactivated  
373 fetal calf serum, 100 U/ml Penicillin, 100 mg/ml Streptomycin, 1 mM sodium pyruvate and 2 mM L-Alanyl L-  
374 glutamine (all Biochrom). The next day, non-adherent cells were transferred to new dishes and differentiated  
375 for six days in RPMI medium (supplemented as described) containing 30 % L929 supernatant. An equal amount  
376 of fresh differentiation medium was added after three days. Four days later, the attached cells were harvested,  
377 counted and seeded in RPMI + 15 % L929 supernatant to perform the experiments. Cells were cultured at 37°C  
378 and 5 % CO<sub>2</sub> under atmospheric oxygen.

379

### 380 Micronucleus flow assay

381 Retrobulbar blood sample was mixed with heparin/PBS (250 units/ml, Biochrom) and fixed by adding 20 μl of  
382 the mixture to 2 ml ice-cold methanol, inverted and stored at -80 °C. Quantification of micronucleated  
383 erythrocytes was performed as described previously (Balmus et al., 2015). Briefly, fixed blood cells were washed  
384 in bicarbonate buffer and stained using antibodies against CD71 (Southern Biotech, #1720-02, 1:200) and Ter119  
385 (eBioscience, #48-5921-82, 1:500) in the presence of 1 μg/μl RNase A. After washing and addition of 1 μg/ml PI,

386 cells were analyzed by flow cytometry and gated for single Ter119<sup>+</sup> CD71<sup>+</sup> PI<sup>+</sup> micronucleated reticulocytes (MN-  
387 Ret) and Ter119<sup>+</sup> CD71<sup>-</sup> PI<sup>+</sup> micronucleated normochromatic erythrocytes (MN-NCE).

388

389 Transcriptomics of peritoneal macrophages

390 Peritoneal macrophages (DAPI<sup>-</sup>, CD11b<sup>hi</sup>, F4/80<sup>hi</sup>) were isolated by FACS using antibodies against CD11b  
391 (eBioscience, #11-0112, 1:1600) and F4/80 (Biolegend, #123114, 1:200), and total RNA was extracted using  
392 RNeasy Plus Mini Kit (Qiagen). For each experiment equal amounts of total RNA were used for poly-dT  
393 enrichment before library preparation and sequencing was performed as described before (Schubert et al.,  
394 2022). Reads were mapped to mouse genome GRCh39 followed by normalization, exploratory and differential  
395 expression analysis using DESeq2 (Love et al., 2014). Unless otherwise stated, DEG lists were generated by  
396 comparing all mutant mouse lines to the respective wild type group in each experiment and sorted in according  
397 to ascending padj. All transcripts with padj<0.05 were subjected to GSEA (Subramanian et al., 2005). To  
398 generate heatmaps all transcripts with padj<0.05 in the comparison Samhd1<sup>Δ/Δ</sup> vs. Samhd1<sup>+/-</sup> were extracted  
399 from lists containing normalized read counts of all genotypes in the respective experiment and the resulting sub  
400 list was displayed using Morpheus (<https://software.broadinstitute.org/morpheus>). New datasets are currently  
401 being deposited in the GEO database. Analysis in Figure 1 has been performed on a previously generated  
402 dataset GSE45358.

403

404 Quantification of phosphorylated histone H2AX

405 25.000 MEFs were plated into 8-well chamber slides. Cells were left at 37°C over night to attach to the slide.  
406 After incubation, cells were washed in PBS, fixed in ice-cold methanol and washed again. For quantification of  
407 phosphorylated histone H2AX (γH2AX), slides were blocked at RT for 1 h in 1x Blocking reagent (Roche) and  
408 incubated at 4°C over night with a phospho-histone H2AX (pSer139) antibody (Cell Signaling Technology,  
409 #2577, 1:50). After washing with PBS, slides were incubated with a goat anti-rabbit-AF488 antibody (Thermo  
410 Fisher Scientific, #A-11034, 1:500) for 1h at RT in the dark. Slides were washed and nuclei were counterstained  
411 with 10 μg/ml DAPI in the mounting solution. Imaging was done on a Keyence fluorescence microscope and  
412 analyzed using ImageJ software (NIH). γH2AX foci in at least 50 fibroblast nuclei were counted. As positive  
413 control, wild type MEFs were gamma-irradiated with a dose of 10 Gy and analyzed 1 hour later.

414

415 Histology

416 Thymi were formalin-fixed, paraffin-embedded, and cut into 3 μm sections. For H&E (haematoxylin-eosin)  
417 staining, sections were dyed with Mayer's hemalum solution for 2 min, followed by staining with eosin and rinse  
418 with water for 30 seconds. The preparations were dehydrated again in an ascending alcohol series and washed  
419 in xylene. H&E sections were evaluated by a board-certified pathologist on a Zeiss Axioskop 2 microscope and  
420 photographs were made with an Axiocam 503 color camera using ZEN 2.5 (blue edition) software (Zeiss).

421 Multiplex immunohistochemical staining against CD3, CD4, and CD8 to assess T cell composition in thymi was  
422 performed on a Ventana Discovery Ultra Instrument. Briefly, antigen retrieval using cell conditioning 1 solution  
423 (Ventana Medical Systems) was performed at 95°C for 32 min, followed by incubation with the primary antibody  
424 against CD8 (eBioscience, #14-0195-82, 1:100) at 36°C for 32 min, the HRP-coupled secondary anti-rat  
425 OmniMap antibody (Ventana Medical Systems) for 12 min and finally Opal 520 fluorophore (Akoya Biosciences,  
426 1:100) at RT for 8 min. Primary and secondary antibodies were removed by denaturation at 100°C for 24 min in  
427 cell conditioning 2 buffer (Ventana Medical Systems). The above described steps were repeated for CD4  
428 (abcam, #ab183685, 1:500) with OmniMap anti-rabbit-HRP and Opal 570 fluorophore (Akoya Biosciences,  
429 1:1000), and lastly CD3 (abcam, #ab16669, 1:50) with OmniMap anti-rabbit-HRP and Opal 690 fluorophore  
430 (Akoya Biosciences, 1:50). Finally, sections were counterstained with DAPI (Merck) and mounted with  
431 Fluoromount G mounting media (Southern Biotech). Sections were scanned at 100x magnification, regions of  
432 interest defined using Phenochart software (Akoya Biosciences), and multispectral images acquired at x200  
433 magnification using the Ventra 3.0 Automated Imaging System (Akoya Biosciences). Upon spectral unmixing  
434 using inForm Software (Akoya Biosciences), images were exported and processed in ImageJ (NIH).

435

436 Flow cytometry

437 Thymi were homogenized and passed through a 70  $\mu$ m cell filter. Following washing with ice-cold FACS buffer  
438 (PBS/ 2 %FCS/ 2mM EDTA), cells were filtered again through a 70  $\mu$ m cell filter. On samples from peripheral  
439 blood erythrocytes were lysed if leucocytes were analyzed. Cells were incubated with anti-CD16/CD32  
440 (Biolegend, #101302, 1:200) at RT for 10 min to block Fc receptors and stained with the following antibodies in  
441 FACS buffer at 4 °C for 30 min: CD3e (eBioscience, # 11-0031, 1:200 or # 17-0031, 1:100), CD4 (eBioscience, #53-  
442 0041, 1:200), CD8a (eBioscience, #25-0081, 1:600), CD11b (eBioscience, #11-0112, 1:1600), CD19 (eBioscience,  
443 #25-0193, 1:200), CD25 (eBioscience, #12-0251, 1:800), CD44 (eBioscience, # 48-0441, 1:200), CD45R (B220)  
444 (eBioscience, # 47-0452, 1:100) and Ly-6A/E (Sca-1) (eBioscience, #17-5981, 1:200). After incubation, cells were  
445 washed and resuspended in FACS buffer. For dead cell exclusion, 1  $\mu$ g/ml of PI was added to the cell suspension  
446 shortly before the analysis. Cells were analyzed using the FACSaria III (BD Bioscience) and evaluated with  
447 FlowJo Version 10 (Tree Star).

448 Peripheral blood was stained for Sca-1<sup>+</sup> within the CD3<sup>+</sup> and CD19<sup>+</sup> populations.

449

450 Telomere integrity

451 Quantification of telomere integrity was done with metaphase telomere Fluorescence In Situ Hybridization  
452 (FISH). Metaphase spreads were performed as previously published (Poon and Lansdorp, 2001). Briefly, the cells  
453 were cultured in 10 cm petri dishes and grown to 60% confluency. The cells were treated with 0.2 $\mu$ g/ml Colcemid  
454 (Merck #10 295 892 001) for 3 hours and incubated with hypotonic solution (75mM KCl). Swollen cells were  
455 washed with fixative solution (methanol:glacial acetic acid 3:1) and dropped on superfrost microscopic slides.  
456 Telomeres were stained with TelC-Alexa488 labelled PNA probe (Panagene, #F1004) as previously published  
457 (Awad et al., 2020). The slides were mounted with Fluoroshield mounting media containing DAPI (Sigma,  
458 #F6057-20ML) to stain the chromosomes. Images were acquired using a ZEISS Axio Observer microscope. The  
459 obtained images were analysed by evaluating the average telomere integrity per metaphase. Depending on the  
460 signal, the telomere phenotypes were categorised to fragile, outside, apposition and fusion.

461

462 Quantitative RT-PCR

463 Total RNA was isolated using NucleoSpin RNA Kit (Macherey-Nagel) and reverse transcribed into cDNA using  
464 PrimeScript RT Reagent Kit (Takara) following the manufacturer's instructions. Quantitative RT-PCR using  
465 Luna® Universal qPCR Master Mix (New England BioLabs) was performed with the following cycling conditions  
466 on a CFX384 Touch Real-Time PCR Detection System (Bio-Rad): 10 min 95°C, 40 cycles of 95°C for 20 s, 60°C  
467 for 30 s. The used qRT-PCR primers are listed in Supplementary Table 1. Transcript levels were normalized to  
468 the housekeeping gene Tbp1. All samples were run in technical triplicates.

469

470 CRISPR/Cas9 gene targeting in MEFs and LL171 cells

471 Cells were transfected with pSpCas9(BB)-2A-GFP (px458, Addgene) containing guide RNAs targeting genes  
472 *cGas*, *Irf1h1* or *Ddx58*. Target sequences are given in Supplementary Table 1. Cells were selected with 3  $\mu$ g/ml  
473 puromycin for 72 h and single cell clones were isolated in a 96-well format. Genotyping was performed by  
474 amplicon deep sequencing on a MiSeq using a protocol described by Lange et al., 2014, that was adapted to the  
475 target loci. Knock out of the target genes was determined genetically using the Outknocker tool (Schmid-Burgk  
476 et al., 2014) and functionally by the lack of response to specific ligands (Fig. S3).

477

478 LL171 luciferase reporter assay

479 ISRE luciferase reporter expressing LL171 cells were cultured in DMEM (Gibco) supplemented with 10 % heat-  
480 inactivated fetal calf serum, 100 U/ml Penicillin, 100 mg/ml Streptomycin, 1x non-essential amino acids (all  
481 Biochrom) and 600  $\mu$ g/ml G418. To analyze luciferase activity in cell supernatant, LL171 cells were seeded in  
482 supplemented DMEM w/o G418 in 96-well plates. Once cells are attached, DMEM was removed and IFN-  
483 containing cell supernatant was added over night to the cells. Luciferase assay was performed using the  
484 SpectraMax® Glo Steady-Luc™ Reporter Assay Kit (Molecular Devices) according to the manufacturer's

485 instructions and relative luciferase activity was measured at the LUMIstar Omega (BMG Labtech) microplate  
486 reader.

487

488 Western Blot

489 Cell pellets from *GFP-cGas<sup>K1/K1</sup>* and control BMDMs were lysed in 2x Laemmli buffer and incubated at 95 °C for  
490 5 min. Proteins were separated on a 12 % denaturing acrylamide gel and subsequently transferred onto a  
491 nitrocellulose membrane (Amersham Hybond-ECL, GE Healthcare). Membrane was blocked using 1x  
492 Roti®Block (Carl Roth) for one hour and incubated over night at 4 °C with the primary antibodies against cGAS  
493 (Cell Signaling Technology, #31659, 1:1000), β-actin (Cell Signaling Technology, #4970, 1:10.000) and  
494 Cyclophilin B (Cell Signaling Technology, #43603, 1:20.000), diluted in 1x Roti®Block. Following washing with  
495 TBS/0.1% Tween (TBS-T), the membrane was incubated for one hour at RT with peroxidase-conjugated goat  
496 anti-rabbit secondary antibody (Cell Signaling Technology, #7074, 1:1000) and washed again. The Amersham  
497 ECL Prime Western Blotting Detection Reagent (GE Healthcare) was used for protein visualization using the  
498 Fusion FX (Vilber Lourmat) and Fusion FX7 Advanced imaging software. Signals were densitometrically  
499 analyzed using ImageJ software (NIH).

500

501 Statistical Analysis

502 Data are shown as means ± SD. Statistical analysis was performed using GraphPad Prism 9. To compare the  
503 mean of two groups, Student's t test (unpaired t test, two-tailed, 95% confidence intervals) was used. For the  
504 comparison of more groups one-way ANOVA or two-way ANOVA followed by either Tukey's or Sidak's multiple  
505 comparison test were used. Log-rank test was used to compare survival data. Significance levels in each figure  
506 are stated as follows: p ≤ 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001.

507

508 Supplementary Table 1. Oligonucleotides

Name	Forward oligo (5'-3')	Reverse oligo (5'-3')
Tbp1	TCTACCGTGAATCTTGGCTGTAA	TTCTCATGATGACTGCAGCAA
Ifi44	GGCACATCTTAAAGGGCCACACTC	CTGTCCTTCAGCAGTGGGTCATG
Pydc4	CATTCCAGAACTTGCAGCTCGTG	GTAAGTGGAGGAGGGCTGGATTC
Oasl1	CGTTGTGCCCGCTACAGAGCC	GCTGCAGCTCGCTGAAGGATGG
Rsad2	CAAGCGAGGACTGCTTCTGCTC	GCAGAATCTCACAAGCTTGCC
Usp18	CACAACATCGGACAGACGTGTTGC	CTTCCTCTCTTCTGCACTCCGAG
Isg15	TGGTACAGAACTGCAGCGAG	CAGCCAGAACTGGTCTTCGT
Cxcl10	GCCGTCATTTTCTGCCTCAT	GCTTCCCTATGGCCCTCATT
cGas-GO1	CACCGGTCGGGGCGCGCTTCGCGGA	AAACTCCGCGAAGCGCGCCCGACC
cGas-GO2	CACCGACGCGGCAGGAGCCACCGCG	AAACCGCGGTGGCTCCTGCCGCGT
Ddx58-GO1int	CAACCG TTGAAAGTCCCAACTTTCGA	AAAC TCGAAAGTTGGGACTTTCAA C
Ddx58-GO2int	CAACCG GGAATGTGAAGAAATCAGAC	AAAC GTCTGATTTCTTCACATTCC C
Ifih1-GO1int	CAACCG ATTTCTGCTGCAGGAAACAG	CAACG CTATTCCAAGAACTAACAGG
Ifih1-GO2int	CAACCG CTATTCCAAGAACTAACAGG	AAAC CCTGTTAGTTCTTGAATAG C
cGas_NGS	ACACTCTTCCCTACACGACGCTCTTCCGAT CTGACTTCACGCGTGCTCCTGCGC	GTGACTGGAGTTCAGACGTGTGCTCTTCC GATCTACGACTTTCGCGCCTCGGGATC
Ddx58_NGS	ACACTCTTCCCTACACGACGCTCTTCCGAT CTCCCTTGCCACTGATTTGAACAGG	GTGACTGGAGTTCAGACGTGTGCTCTTCC GATCTTGGGTTTCAATTATCCTTGGGCC
Ifih1_NGS	ACACTCTTCCCTACACGACGCTCTTCCGAT CTACACACTGACCCACTTCATCAGCC	GTGACTGGAGTTCAGACGTGTGCTCTTCC GATCTCTCCACTCCCTTACCCCTACCTC

509

510 **Author contributions**

511 Conceptualization - R.B.; Methodology – R.B., S.C.R., T.S.; A.G., Li.M., Validation Verification - Li.M., Me.H.;  
512 Formal Analysis R.B., A.G., M.A.M., Me.H., Y.G., S.R.A., R.O., N.S., Lu.M., Li.M., M.S.; Investigation - S.C.R.,  
513 M.A.M., Y.G., S.R.A., R.O., L.S., N.S., B.U., Lu.M., Li.M., M.S., A.G., R.B.; Resources - M.S., S.B., T.Z., N.M.;  
514 Data Curation – Y.G.; Writing – Original Draft - R.B., T.S., N.S.; Writing – Review & Editing - R.B., T.S., N.S.,

515 Visualization – R.B., N.S., M.H, Lu.M.; Supervision - R.B.,A.R, K.P., A.G.; Funding Acquisition – R.B., A.R.,  
516 K.P.,S.B.

517

## 518 Acknowledgements

519 R.B., A.R., K.P., S.B, T.Z. were supported by the DFG TRR/SFB237. R.B. was additionally supported by the DFG  
520 (BE-5877/2-1) and by an AGS Research Award. T.G. was supported by DFG 401821119/GRK 2504.

521

## 522 References

523 Ablasser, A., and S. Hur. 2020. Regulation of cGAS- and RLR-mediated immunity to nucleic acids. *Nat*  
524 *Immunol.* 21:17–29. doi:10.1038/s41590-019-0556-1.

525 Ahmad, S., X. Mu, F. Yang, E. Greenwald, J.W. Park, E. Jacob, C.-Z. Zhang, and S. Hur. 2018. Breaching Self-  
526 Tolerance to Alu Duplex RNA Underlies MDA5-Mediated Inflammation. *Cell.* 172:797-810.e13.

527 doi:10.1016/j.cell.2017.12.016.

528 Andreeva, L., B. Hiller, D. Kostrewa, C. Lässig, C.C. de Oliveira Mann, D. Jan Drexler, A. Maiser, M. Gaidt, H.  
529 Leonhardt, V. Hornung, and K.-P. Hopfner. 2017. cGAS senses long and HMGB/TFAM-bound U-turn  
530 DNA by forming protein-DNA ladders. *Nature.* 549:394–398. doi:10.1038/nature23890.

531 Antonucci, J.M., C. St Gelais, S. de Silva, J.S. Yount, C. Tang, X. Ji, C. Shepard, Y. Xiong, B. Kim, and L. Wu.  
532 2016. SAMHD1-mediated HIV-1 restriction in cells does not involve ribonuclease activity. *Nat. Med.*  
533 22:1072–1074. doi:10.1038/nm.4163.

534 Awad, A., G. Glousker, N. Lamm, S. Tawil, N. Hourvitz, R. Smoom, P. Revy, and Y. Tzfati. 2020. Full length  
535 RTEL1 is required for the elongation of the single-stranded telomeric overhang by telomerase.  
536 *Nucleic Acids Res.* 48:7239–7251. doi:10.1093/nar/gkaa503.

537 Aye, Y., M. Li, M.J.C. Long, and R.S. Weiss. 2015. Ribonucleotide reductase and cancer: biological mechanisms  
538 and targeted therapies. *Oncogene.* 34:2011–2021. doi:10.1038/onc.2014.155.

539 Baker, S.M., C.E. Bronner, L. Zhang, A.W. Plug, M. Robatzek, G. Warren, E.A. Elliott, J. Yu, T. Ashley, N.  
540 Arnheim, R.A. Flavell, and R.M. Liskay. 1995. Male mice defective in the DNA mismatch repair gene  
541 PMS2 exhibit abnormal chromosome synapsis in meiosis. *Cell.* 82:309–319. doi:10.1016/0092-  
542 8674(95)90318-6.

543 Balmus, G., N.A. Karp, B.L. Ng, S.P. Jackson, D.J. Adams, and R.E. McIntyre. 2015. A high-throughput in vivo  
544 micronucleus assay for genome instability screening in mice. *Nat Protoc.* 10:205–215.  
545 doi:10.1038/nprot.2015.010.

546 Baugh, E.H., H. Ke, A.J. Levine, R.A. Bonneau, and C.S. Chan. 2018. Why are there hotspot mutations in the  
547 TP53 gene in human cancers? *Cell Death Differ.* 25:154–160. doi:10.1038/cdd.2017.180.

548 Behrendt, R., T. Schumann, A. Gerbaulet, L.A. Nguyen, N. Schubert, D. Alexopoulou, U. Berka, S. Lienenklaus,  
549 K. Peschke, K. Gibbert, S. Wittmann, D. Lindemann, S. Weiss, A. Dahl, R. Naumann, U. Dittmer, B.  
550 Kim, W. Mueller, T. Gramberg, and A. Roers. 2013. Mouse SAMHD1 has antiretroviral activity and  
551 suppresses a spontaneous cell-intrinsic antiviral response. *Cell Rep.* 4:689–696.  
552 doi:10.1016/j.celrep.2013.07.037.

553 Bloch, N., S. Gläsker, P. Sitaram, H. Hofmann, C.N. Shepard, M.L. Schultz, B. Kim, and N.R. Landau. 2017. A  
554 Highly Active Isoform of Lentivirus Restriction Factor SAMHD1 in Mouse. *Journal of Biological*  
555 *Chemistry.* 292:1068–1080. doi:10.1074/jbc.M116.743740.

556 Cervantes-Barragán, L., U. Kalinke, R. Züst, M. König, B. Reizis, C. López-Macías, V. Thiel, and B. Ludewig.  
557 2009. Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine  
558 coronavirus infection. *J. Immunol.* 182:1099–1106. doi:10.4049/jimmunol.182.2.1099.

- 559 Choi, J., J. Ryoo, C. Oh, S. Hwang, and K. Ahn. 2015. SAMHD1 specifically restricts retroviruses through its  
560 RNase activity. *Retrovirology*. 12:46. doi:10.1186/s12977-015-0174-4.
- 561 Clapes, T., A. Polyzou, P. Prater, Sagar, A. Morales-Hernández, M.G. Ferrarini, N. Kehrer, S. Lefkopoulos, V.  
562 Bergo, B. Hummel, N. Obier, D. Maticzka, A. Bridgeman, J.S. Herman, I. Ilik, L. Klauyél, J. Rehwinkel,  
563 S. McKinney-Freeman, R. Backofen, A. Akhtar, N. Cabezas-Wallscheid, R. Sawarkar, R. Rebollo, D.  
564 Grün, and E. Trompouki. 2021. Chemotherapy-induced transposable elements activate MDA5 to  
565 enhance haematopoietic regeneration. *Nat Cell Biol*. 23:704–717. doi:10.1038/s41556-021-00707-9.
- 566 Clifford, R., T. Louis, P. Robbe, S. Ackroyd, A. Burns, A.T. Timbs, G. Wright Colopy, H. Dreau, F. Sigaux, J.G.  
567 Judde, M. Rotger, A. Telenti, Y.-L. Lin, P. Pasero, J. Maelfait, M. Titsias, D.R. Cohen, S.J. Henderson,  
568 M.T. Ross, D. Bentley, P. Hillmen, A. Pettitt, J. Rehwinkel, S.J.L. Knight, J.C. Taylor, Y.J. Crow, M.  
569 Benkirane, and A. Schuh. 2014. SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and  
570 is involved in response to DNA damage. *Blood*. 123:1021–1031. doi:10.1182/blood-2013-04-490847.
- 571 Coquel, F., M.-J. Silva, H. Técher, K. Zadorozhny, S. Sharma, J. Nieminuszczy, C. Mettling, E. Dardillac, A.  
572 Barthe, A.-L. Schmitz, A. Promonet, A. Cribier, A. Sarrazin, W. Niedzwiedz, B. Lopez, V. Costanzo, L.  
573 Krejci, A. Chabes, M. Benkirane, Y.-L. Lin, and P. Pasero. 2018. SAMHD1 acts at stalled replication  
574 forks to prevent interferon induction. *Nature*. 557:57–61. doi:10.1038/s41586-018-0050-1.
- 575 Crow, Y.J., and D.B. Stetson. 2021. The type I interferonopathies: 10 years on. *Nat Rev Immunol*. 1–13.  
576 doi:10.1038/s41577-021-00633-9.
- 577 Daddacha, W., A.E. Koyen, A.J. Bastien, P.E. Head, V.R. Dhere, G.N. Nabeta, E.C. Connolly, E. Werner, M.Z.  
578 Madden, M.B. Daly, E.V. Minten, D.R. Whelan, A.J. Schlafstein, H. Zhang, R. Anand, C. Doronio, A.E.  
579 Withers, C. Shepard, R.K. Sundaram, X. Deng, W.S. Dynan, Y. Wang, R.S. Bindra, P. Cejka, E.  
580 Rothenberg, P.W. Doetsch, B. Kim, and D.S. Yu. 2017. SAMHD1 Promotes DNA End Resection to  
581 Facilitate DNA Repair by Homologous Recombination. *Cell Rep*. 20:1921–1935.  
582 doi:10.1016/j.celrep.2017.08.008.
- 583 Davenne, T., J. Klintman, S. Sharma, R.E. Rigby, H.T.W. Blest, C. Cursi, A. Bridgeman, B. Dadonaite, K. De  
584 Keersmaecker, P. Hillmen, A. Chabes, A. Schuh, and J. Rehwinkel. 2020. SAMHD1 Limits the Efficacy  
585 of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP. *Cell Reports*.  
586 31:107640. doi:10.1016/j.celrep.2020.107640.
- 587 De Cecco, M., T. Ito, A.P. Petrashen, A.E. Elias, N.J. Skvir, S.W. Criscione, A. Caligiana, G. Broccoli, E.M.  
588 Adney, J.D. Boeke, O. Le, C. Beauséjour, J. Ambati, K. Ambati, M. Simon, A. Seluanov, V. Gorbunova,  
589 P.E. Slagboom, S.L. Helfand, N. Neretti, and J.M. Sedivy. 2019. L1 drives IFN in senescent cells and  
590 promotes age-associated inflammation. *Nature*. 566:73–78. doi:10.1038/s41586-018-0784-9.
- 591 Demaria, O., S. Cornen, M. Daëron, Y. Morel, R. Medzhitov, and E. Vivier. 2019. Harnessing innate immunity in  
592 cancer therapy. *Nature*. 574:45–56. doi:10.1038/s41586-019-1593-5.
- 593 Du, M., and Z.J. Chen. 2018. DNA-induced liquid phase condensation of cGAS activates innate immune  
594 signaling. *Science*. 361:704–709. doi:10.1126/science.aat1022.
- 595 Gao, D., T. Li, X.-D. Li, X. Chen, Q.-Z. Li, M. Wight-Carter, and Z.J. Chen. 2015. Activation of cyclic GMP-AMP  
596 synthase by self-DNA causes autoimmune diseases. *Proc. Natl. Acad. Sci. U.S.A.* 112:E5699–5705.  
597 doi:10.1073/pnas.1516465112.
- 598 Gentili, M., X. Lahaye, F. Nadalin, G.P.F. Nader, E.P. Lombardi, S. Herve, N.S. De Silva, D.C. Rookhuizen, E.  
599 Zueva, C. Goudot, M. Maurin, A. Bochnakian, S. Amigorena, M. Piel, D. Fachinetti, A. Londoño-  
600 Vallejo, and N. Manel. 2019. The N-Terminal Domain of cGAS Determines Preferential Association  
601 with Centromeric DNA and Innate Immune Activation in the Nucleus. *Cell Rep*. 26:3798.  
602 doi:10.1016/j.celrep.2019.03.049.
- 603 Giordano, A.M.S., M. Luciani, F. Gatto, M. Abou Alezz, C. Beghè, L. Della Volpe, A. Migliara, S. Valsoni, M.  
604 Genua, M. Dzieciatkowska, G. Frati, J. Tahraoui-Bories, S.C. Giliani, S. Orcesi, E. Fazzi, R. Ostuni, A.

- 605 D'Alessandro, R. Di Micco, I. Merelli, A. Lombardo, M.A.M. Reijns, N. Gromak, A. Gritti, and A.  
606 Kajaste-Rudnitski. 2022. DNA damage contributes to neurotoxic inflammation in Aicardi-Goutières  
607 syndrome astrocytes. *Journal of Experimental Medicine*. 219:e20211121. doi:10.1084/jem.20211121.
- 608 Gitlin, L., W. Barchet, S. Gilfillan, M. Cella, B. Beutler, R.A. Flavell, M.S. Diamond, and M. Colonna. 2006.  
609 Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and  
610 encephalomyocarditis picornavirus. *Proceedings of the National Academy of Sciences*. 103:8459–  
611 8464. doi:10.1073/pnas.0603082103.
- 612 Goldstone, D.C., V. Ennis-Adeniran, J.J. Hedden, H.C.T. Groom, G.I. Rice, E. Christodoulou, P.A. Walker, G.  
613 Kelly, L.F. Haire, M.W. Yap, L.P.S. de Carvalho, J.P. Stoye, Y.J. Crow, I.A. Taylor, and M. Webb. 2011.  
614 HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. *Nature*.  
615 480:379–382. doi:10.1038/nature10623.
- 616 Gray, E.E., P.M. Treuting, J.J. Woodward, and D.B. Stetson. 2015. Cutting Edge: cGAS Is Required for Lethal  
617 Autoimmune Disease in the Trex1-Deficient Mouse Model of Aicardi-Goutières Syndrome. *J.*  
618 *Immunol*. 195:1939–1943. doi:10.4049/jimmunol.1500969.
- 619 Gutierrez-Merino, J., B. Isla, T. Combes, F. Martinez-Estrada, and C. Maluquer De Motes. 2020. Beneficial  
620 bacteria activate type-I interferon production via the intracellular cytosolic sensors STING and MAVS.  
621 *Gut Microbes*. 11:771–788. doi:10.1080/19490976.2019.1707015.
- 622 Haag, S.M., M.F. Gulen, L. Reymond, A. Gibelin, L. Abrami, A. Decout, M. Heymann, F.G. van der Goot, G.  
623 Turcatti, R. Behrendt, and A. Ablasser. 2018. Targeting STING with covalent small-molecule  
624 inhibitors. *Nature*. 559:269–273. doi:10.1038/s41586-018-0287-8.
- 625 Herold, N., S.G. Rudd, L. Ljungblad, K. Sanjiv, I.H. Myrberg, C.B.J. Paulin, Y. Heshmati, A. Hagenkort, J.  
626 Kutzner, B.D.G. Page, J.M. Calderón-Montaño, O. Loseva, A.-S. Jemth, L. Bulli, H. Axelsson, B. Tesi,  
627 N.C.K. Valerie, A. Höglund, J. Bladh, E. Wiita, M. Sundin, M. Uhlin, G. Rassidakis, M. Heyman, K.P.  
628 Tamm, U. Warpman-Berglund, J. Walfridsson, S. Lehmann, D. Grandér, T. Lundbäck, P. Kogner, J.-I.  
629 Henter, T. Helleday, and T. Schaller. 2017. Targeting SAMHD1 with the Vpx protein to improve  
630 cytarabine therapy for hematological malignancies. *Nat. Med*. 23:256–263. doi:10.1038/nm.4265.
- 631 Hiller, B., A. Hoppe, C. Haase, C. Hiller, N. Schubert, W. Müller, M.A.M. Reijns, A.P. Jackson, T.A. Kunkel, J.  
632 Wenzel, R. Behrendt, and A. Roers. 2018. Ribonucleotide Excision Repair Is Essential to Prevent  
633 Squamous Cell Carcinoma of the Skin. *Cancer Res*. 78:5917–5926. doi:10.1158/0008-5472.CAN-18-  
634 1099.
- 635 Hrecka, K., C. Hao, M. Gierszewska, S.K. Swanson, M. Kesik-Brodacka, S. Srivastava, L. Florens, M.P.  
636 Washburn, and J. Skowronski. 2011. Vpx relieves inhibition of HIV-1 infection of macrophages  
637 mediated by the SAMHD1 protein. *Nature*. 474:658–661. doi:10.1038/nature10195.
- 638 Hu, S., Y. Fang, X. Chen, T. Cheng, M. Zhao, M. Du, T. Li, M. Li, Z. Zeng, Y. Wei, Z. Gu, C. Zhang, L. Sun, and  
639 Z.J. Chen. 2021. cGAS restricts colon cancer development by protecting intestinal barrier integrity.  
640 *Proc Natl Acad Sci U S A*. 118:e2105747118. doi:10.1073/pnas.2105747118.
- 641 Ishizuka, J.J., R.T. Manguso, C.K. Cheruiyot, K. Bi, A. Panda, A. Iracheta-Vellve, B.C. Miller, P.P. Du, K.B. Yates,  
642 J. Dubrot, I. Buchumenski, D.E. Comstock, F.D. Brown, A. Ayer, I.C. Kohnle, H.W. Pope, M.D.  
643 Zimmer, D.R. Sen, S.K. Lane-Reticker, E.J. Robitschek, G.K. Griffin, N.B. Collins, A.H. Long, J.G.  
644 Doench, D. Kozono, E.Y. Levanon, and W.N. Haining. 2019. Loss of ADAR1 in tumours overcomes  
645 resistance to immune checkpoint blockade. *Nature*. 565:43–48. doi:10.1038/s41586-018-0768-9.
- 646 Jacks, T., L. Remington, B.O. Williams, E.M. Schmitt, S. Halachmi, R.T. Bronson, and R.A. Weinberg. 1994.  
647 Tumor spectrum analysis in p53-mutant mice. *Curr Biol*. 4:1–7. doi:10.1016/s0960-9822(00)00002-6.
- 648 Kretschmer, S., C. Wolf, N. König, W. Staroske, J. Guck, M. Häusler, H. Luksch, L.A. Nguyen, B. Kim, D.  
649 Alexopoulou, A. Dahl, A. Rapp, M.C. Cardoso, A. Shevchenko, and M.A. Lee-Kirsch. 2015. SAMHD1

- 650 prevents autoimmunity by maintaining genome stability. *Ann. Rheum. Dis.* 74:e17.  
651 doi:10.1136/annrheumdis-2013-204845.
- 652 Laguette, N., B. Sobhian, N. Casartelli, M. Ringeard, C. Chable-Bessia, E. Ségéral, A. Yatim, S. Emiliani, O.  
653 Schwartz, and M. Benkirane. 2011. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1  
654 restriction factor counteracted by Vpx. *Nature.* 474:654–657. doi:10.1038/nature10117.
- 655 Lienenklaus, S., M. Cornitescu, N. Zietara, M. Łyszkiewicz, N. Gekara, J. Jabłńska, F. Edenhofer, K. Rajewsky,  
656 D. Bruder, M. Hafner, P. Staeheli, and S. Weiss. 2009. Novel reporter mouse reveals constitutive and  
657 inflammatory expression of IFN-beta in vivo. *J. Immunol.* 183:3229–3236.  
658 doi:10.4049/jimmunol.0804277.
- 659 Lima-Junior, D.S., S.R. Krishnamurthy, N. Bouladoux, N. Collins, S.-J. Han, E.Y. Chen, M.G. Constantinides,  
660 V.M. Link, A.I. Lim, M. Enamorado, C. Cataisson, L. Gil, I. Rao, T.K. Farley, G. Koroleva, J. Attig, S.H.  
661 Yuspa, M.A. Fischbach, G. Kassiotis, and Y. Belkaid. 2021. Endogenous retroviruses promote  
662 homeostatic and inflammatory responses to the microbiota. *Cell.* 184:3794–3811.e19.  
663 doi:10.1016/j.cell.2021.05.020.
- 664 Lin, C.-Y.G., A.C. Näger, T. Lunardi, A. Vančevska, G. Lossaint, and J. Lingner. 2021. The human telomeric  
665 proteome during telomere replication. *Nucleic Acids Research.* 49:12119–12135.  
666 doi:10.1093/nar/gkab1015.
- 667 Love, M.I., W. Huber, and S. Anders. 2014. Moderated estimation of fold change and dispersion for RNA-seq  
668 data with DESeq2. *Genome Biology.* 15:550. doi:10.1186/s13059-014-0550-8.
- 669 Mackenzie, K.J., P. Carroll, C.-A. Martin, O. Murina, A. Fluteau, D.J. Simpson, N. Olova, H. Sutcliffe, J.K.  
670 Rainger, A. Leitch, R.T. Osborn, A.P. Wheeler, M. Nowotny, N. Gilbert, T. Chandra, M.A.M. Reijns,  
671 and A.P. Jackson. 2017. cGAS surveillance of micronuclei links genome instability to innate immunity.  
672 *Nature.* 548:461–465. doi:10.1038/nature23449.
- 673 Maelfait, J., A. Bridgeman, A. Benlahrech, C. Cursi, and J. Rehwinkel. 2016. Restriction by SAMHD1 Limits  
674 cGAS/STING-Dependent Innate and Adaptive Immune Responses to HIV-1. *Cell Rep.* 16:1492–1501.  
675 doi:10.1016/j.celrep.2016.07.002.
- 676 Majerska, J., M. Feretzaki, G. Glousker, and J. Lingner. 2018. Transformation-induced stress at telomeres is  
677 counteracted through changes in the telomeric proteome including SAMHD1. *Life Science Alliance.* 1.  
678 doi:10.26508/lsa.201800121.
- 679 Martins, V.C., K. Busch, D. Juraeva, C. Blum, C. Ludwig, V. Rasche, F. Lasitschka, S.E. Mastitsky, B. Brors, T.  
680 Hielscher, H.J. Fehling, and H.-R. Rodewald. 2014. Cell competition is a tumour suppressor  
681 mechanism in the thymus. *Nature.* 509:465–470. doi:10.1038/nature13317.
- 682 Mauney, C.H., and T. Hollis. 2018. SAMHD1: Recurring roles in cell cycle, viral restriction, cancer, and innate  
683 immunity. *Autoimmunity.* 51:96–110. doi:10.1080/08916934.2018.1454912.
- 684 Michallet, M.-C., E. Meylan, M.A. Ermolaeva, J. Vazquez, M. Rebsamen, J. Curran, H. Poeck, M. Bscheider, G.  
685 Hartmann, M. König, U. Kalinke, M. Pasparakis, and J. Tschopp. 2008. TRADD Protein Is an Essential  
686 Component of the RIG-like Helicase Antiviral Pathway. *Immunity.* 28:651–661.  
687 doi:10.1016/j.immuni.2008.03.013.
- 688 Morita, M., G. Stamp, P. Robins, A. Dulic, I. Rosewell, G. Hrivnak, G. Daly, T. Lindahl, and D.E. Barnes. 2004.  
689 Gene-targeted mice lacking the Trex1 (DNase III) 3'→5' DNA exonuclease develop inflammatory  
690 myocarditis. *Mol. Cell. Biol.* 24:6719–6727. doi:10.1128/MCB.24.15.6719-6727.2004.
- 691 de Oliveira Mann, C.C., and K.-P. Hopfner. 2021. Nuclear cGAS: guard or prisoner? *EMBO J.* 40:e108293.  
692 doi:10.15252/embj.2021108293.



- 693 Park, K., J. Ryoo, H. Jeong, M. Kim, S. Lee, S.-Y. Hwang, J. Ahn, D. Kim, H.C. Moon, D. Baek, K. Kim, H.Y. Park,  
694 and K. Ahn. 2021. Aicardi-Goutières syndrome-associated gene SAMHD1 preserves genome integrity  
695 by preventing R-loop formation at transcription–replication conflict regions. *PLoS Genet.*  
696 17:e1009523. doi:10.1371/journal.pgen.1009523.
- 697 Parker, M.T., S. Gopinath, C.E. Perez, M.M. Linehan, J.M. Crawford, A. Iwasaki, and B.D. Lindenbach. 2018.  
698 Innate Immune Priming by cGAS as a Preparatory Countermeasure Against RNA Virus Infection.  
699 bioRxiv. 434027. doi:10.1101/434027.
- 700 Peschke, K., M. Achleitner, K. Frenzel, A. Gerbaulet, S.R. Ada, N. Zeller, S. Lienenklaus, M. Lesche, C. Poulet,  
701 R. Naumann, A. Dahl, U. Ravens, C. Günther, W. Müller, K.-P. Knobeloch, M. Prinz, A. Roers, and R.  
702 Behrendt. 2016. Loss of Trex1 in Dendritic Cells Is Sufficient To Trigger Systemic Autoimmunity. *J.*  
703 *Immunol.* 197:2157–2166. doi:10.4049/jimmunol.1600722.
- 704 Poon, S.S., and P.M. Lansdorp. 2001. Measurements of telomere length on individual chromosomes by image  
705 cytometry. *Methods Cell Biol.* 64:69–96. doi:10.1016/s0091-679x(01)64007-x.
- 706 Rehwinkel, J., J. Maelfait, A. Bridgeman, R. Rigby, B. Hayward, R.A. Liberatore, P.D. Bieniasz, G.J. Towers, L.F.  
707 Moita, Y.J. Crow, D.T. Bonthron, and C. Reis e Sousa. 2013. SAMHD1-dependent retroviral control  
708 and escape in mice. *EMBO J.* 32:2454–2462. doi:10.1038/emboj.2013.163.
- 709 Rentoft, M., K. Lindell, P. Tran, A.L. Chabes, R.J. Buckland, D.L. Watt, L. Marjavaara, A.K. Nilsson, B. Melin, J.  
710 Trygg, E. Johansson, and A. Chabes. 2016. Heterozygous colon cancer-associated mutations of  
711 SAMHD1 have functional significance. *Proc Natl Acad Sci U S A.* 113:4723–4728.  
712 doi:10.1073/pnas.1519128113.
- 713 Rice, G.I., J. Bond, A. Asipu, R.L. Brunette, I.W. Manfield, I.M. Carr, J.C. Fuller, R.M. Jackson, T. Lamb, T.A.  
714 Briggs, M. Ali, H. Gornall, L.R. Couthard, A. Aeby, S.P. Attard-Montalto, E. Bertini, C. Bodemer, K.  
715 Brockmann, L.A. Brueton, P.C. Corry, I. Desguerre, E. Fazzi, A.G. Cazorla, B. Gener, B.C.J. Hamel, A.  
716 Heiberg, M. Hunter, M.S. van der Knaap, R. Kumar, L. Lagae, P.G. Landrieu, C.M. Lourenco, D.  
717 Marom, M.F. McDermott, W. van der Merwe, S. Orcesi, J.S. Prendiville, M. Rasmussen, S.A. Shalev,  
718 D.M. Soler, M. Shinawi, R. Spiegel, T.Y. Tan, A. Vanderver, E.L. Wakeling, E. Wassmer, E. Whittaker,  
719 P. Lebon, D.B. Stetson, D.T. Bonthron, and Y.J. Crow. 2009. Mutations involved in Aicardi-Goutières  
720 syndrome implicate SAMHD1 as regulator of the innate immune response. *Nat. Genet.* 41:829–832.  
721 doi:10.1038/ng.373.
- 722 Rodero, M.P., and Y.J. Crow. 2016. Type I interferon-mediated monogenic autoinflammation: The type I  
723 interferonopathies, a conceptual overview. *J. Exp. Med.* 213:2527–2538. doi:10.1084/jem.20161596.
- 724 Ryoo, J., J. Choi, C. Oh, S. Kim, M. Seo, S.-Y. Kim, D. Seo, J. Kim, T.E. White, A. Brandariz-Nuñez, F. Diaz-  
725 Griffero, C.-H. Yun, J.A. Hollenbaugh, B. Kim, D. Baek, and K. Ahn. 2014. The ribonuclease activity of  
726 SAMHD1 is required for HIV-1 restriction. *Nat. Med.* 20:936–941. doi:10.1038/nm.3626.
- 727 Ryoo, J., S.-Y. Hwang, J. Choi, C. Oh, and K. Ahn. 2016. Reply to SAMHD1-mediated HIV-1 restriction in cells  
728 does not involve ribonuclease activity. *Nat. Med.* 22:1074–1075. doi:10.1038/nm.4164.
- 729 Sauer, J.-D., K. Sotelo-Troha, J. von Moltke, K.M. Monroe, C.S. Rae, S.W. Brubaker, M. Hyodo, Y. Hayakawa,  
730 J.J. Woodward, D.A. Portnoy, and R.E. Vance. 2011. The N-Ethyl-N-Nitrosourea-Induced  
731 Goldenticket Mouse Mutant Reveals an Essential Function of Sting in the In Vivo Interferon Response  
732 to *Listeria monocytogenes* and Cyclic Dinucleotides. *Infect Immun.* 79:688–694.  
733 doi:10.1128/IAI.00999-10.
- 734 Schaupp, L., S. Muth, L. Rogell, M. Kofoed-Branzk, F. Melchior, S. Lienenklaus, S.C. Ganal-Vonarburg, M.  
735 Klein, F. Guendel, T. Hain, K. Schütze, U. Grundmann, V. Schmitt, M. Dorsch, J. Spanier, P.-K. Larsen,  
736 T. Schwanz, S. Jäckel, C. Reinhardt, T. Bopp, S. Danckwardt, K. Mahnke, G.A. Heinz, M.-F.  
737 Mashreghi, P. Durek, U. Kalinke, O. Kretz, T.B. Huber, S. Weiss, C. Wilhelm, A.J. Macpherson, H.  
738 Schild, A. Diefenbach, and H.C. Probst. 2020. Microbiota-Induced Type I Interferons Instruct a Poised  
739 Basal State of Dendritic Cells. *Cell.* 181:1080–1096.e19. doi:10.1016/j.cell.2020.04.022.

- 740 Schmid-Burgk, J.L., T. Schmidt, M.M. Gaidt, K. Pelka, E. Latz, T.S. Ebert, and V. Hornung. 2014. OutKnocker:  
741 a web tool for rapid and simple genotyping of designer nuclease edited cell lines. *Genome Res.*  
742 24:1719–1723. doi:10.1101/gr.176701.114.
- 743 Schneider, C., T. Oellerich, H.-M. Baldauf, S.-M. Schwarz, D. Thomas, R. Flick, H. Bohnenberger, L. Kaderali, L.  
744 Stegmann, A. Cremer, M. Martin, J. Lohmeyer, M. Michaelis, V. Hornung, C. Schliemann, W.E.  
745 Berdel, W. Hartmann, E. Wardelmann, F. Comoglio, M.-L. Hansmann, A.F. Yakunin, G. Geisslinger, P.  
746 Ströbel, N. Ferreirós, H. Serve, O.T. Keppler, and J. Cinatl. 2017. SAMHD1 is a biomarker for  
747 cytarabine response and a therapeutic target in acute myeloid leukemia. *Nat. Med.* 23:250–255.  
748 doi:10.1038/nm.4255.
- 749 Schoggins, J.W., D.A. MacDuff, N. Imanaka, M.D. Gainey, B. Shrestha, J.L. Eitson, K.B. Mar, R.B. Richardson,  
750 A.V. Ratushny, V. Litvak, R. Dabelic, B. Manicassamy, J.D. Aitchison, A. Aderem, R.M. Elliott, A.  
751 García-Sastre, V. Racaniello, E.J. Snijder, W.M. Yokoyama, M.S. Diamond, H.W. Virgin, and C.M.  
752 Rice. 2014. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity.  
753 *Nature.* 505:691–695. doi:10.1038/nature12862.
- 754 Schubert, N., T. Schumann, E. Daum, K. Flade, Y. Ge, L. Hagedorn, W. Edelmann, L. Müller, M. Schmitz, G.  
755 Kuut, V. Hornung, R. Behrendt, and A. Roers. 2022. Genome Replication Is Associated With Release  
756 of Immunogenic DNA Waste. *Frontiers in Immunology.* 13.
- 757 Seamon, K.J., Z. Sun, L.S. Shlyakhtenko, Y.L. Lyubchenko, and J.T. Stivers. 2015. SAMHD1 is a single-  
758 stranded nucleic acid binding protein with no active site-associated nuclease activity. *Nucleic Acids*  
759 *Res.* 43:6486–6499. doi:10.1093/nar/gkv633.
- 760 Simon, M., M.V. Meter, J. Ablaeva, Z. Ke, R.S. Gonzalez, T. Taguchi, M.D. Cecco, K.I. Leonova, V. Kogan, S.L.  
761 Helfand, N. Neretti, A. Roichman, H.Y. Cohen, M.V. Meer, V.N. Gladyshev, M.P. Antoch, A.V.  
762 Gudkov, J.M. Sedivy, A. Seluanov, and V. Gorbunova. 2019. LINE1 Derepression in Aged Wild-Type  
763 and SIRT6-Deficient Mice Drives Inflammation. *Cell Metabolism.* 29:871-885.e5.  
764 doi:10.1016/j.cmet.2019.02.014.
- 765 Subramanian, A., P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, A. Paulovich, S.L.  
766 Pomeroy, T.R. Golub, E.S. Lander, and J.P. Mesirov. 2005. Gene set enrichment analysis: A  
767 knowledge-based approach for interpreting genome-wide expression profiles. *Proceedings of the*  
768 *National Academy of Sciences.* 102:15545–15550. doi:10.1073/pnas.0506580102.
- 769 Thientosapol, E.S., D. Bosnjak, T. Durack, I. Stevanovski, M. van Geldermalsen, J. Holst, Z. Jahan, C. Shepard,  
770 W. Weninger, B. Kim, R. Brink, and C.J. Jolly. 2018. SAMHD1 enhances immunoglobulin  
771 hypermutation by promoting transversion mutation. *Proc Natl Acad Sci U S A.* 115:4921–4926.  
772 doi:10.1073/pnas.1719771115.
- 773 Vanpouille-Box, C., J.A. Hoffmann, and L. Galluzzi. 2019. Pharmacological modulation of nucleic acid sensors -  
774 therapeutic potential and persisting obstacles. *Nat Rev Drug Discov.* 18:845–867. doi:10.1038/s41573-  
775 019-0043-2.
- 776 Wittmann, S., R. Behrendt, K. Eissmann, B. Volkmann, D. Thomas, T. Ebert, A. Cribier, M. Benkirane, V.  
777 Hornung, N.F. Bouzas, and T. Gramberg. 2015. Phosphorylation of murine SAMHD1 regulates its  
778 antiretroviral activity. *Retrovirology.* 12:103. doi:10.1186/s12977-015-0229-6.
- 779 Young, G.R., U. Eksmond, R. Salcedo, L. Alexopoulou, J.P. Stoye, and G. Kassiotis. 2012. Resurrection of  
780 endogenous retroviruses in antibody-deficient mice. *Nature.* 491:774–778. doi:10.1038/nature11599.
- 781 Yu, C.H., A. Bhattacharya, M. Persaud, A.B. Taylor, Z. Wang, A. Bulnes-Ramos, J. Xu, A. Selyutina, A.  
782 Martinez-Lopez, K. Cano, B. Demeler, B. Kim, S.C. Hardies, F. Diaz-Griffero, and D.N. Ivanov. 2021.  
783 Nucleic acid binding by SAMHD1 contributes to the antiretroviral activity and is enhanced by the  
784 GpsN modification. *Nat Commun.* 12:731. doi:10.1038/s41467-021-21023-8.

- 785 Yu, P., W. Lübben, H. Slomka, J. Gebler, M. Konert, C. Cai, L. Neubrandt, O. Prazeres da Costa, S. Paul, S.  
786 Dehnert, K. Döhne, M. Thanisch, S. Storsberg, L. Wiegand, A. Kaufmann, M. Nain, L. Quintanilla-  
787 Martinez, S. Bettio, B. Schnierle, L. Kolesnikova, S. Becker, M. Schnare, and S. Bauer. 2012. Nucleic  
788 Acid-Sensing Toll-like Receptors Are Essential for the Control of Endogenous Retrovirus Viremia and  
789 ERV-Induced Tumors. *Immunity*. 37:867–879. doi:10.1016/j.immuni.2012.07.018.
- 790 Zhang, Q., P. Bastard, Z. Liu, J.L. Pen, M. Moncada-Velez, J. Chen, M. Ogishi, I.K.D. Sabli, S. Hodeib, C. Korol,  
791 J. Rosain, K. Bilguvar, J. Ye, A. Bolze, B. Bigio, R. Yang, A.A. Arias, Q. Zhou, Y. Zhang, F. Onodi, S.  
792 Korniotis, L. Karpf, Q. Philippot, M. Chbihi, L. Bonnet-Madin, K. Dorgham, N. Smith, W.M. Schneider,  
793 B.S. Razoogy, H.-H. Hoffmann, E. Michailidis, L. Moens, J.E. Han, L. Lorenzo, L. Bizien, P. Meade, A.-  
794 L. Neehus, A.C. Ugurbil, A. Corneau, G. Kerner, P. Zhang, F. Rapaport, Y. Seeleuthner, J. Manry, C.  
795 Masson, Y. Schmitt, A. Schlüter, T.L. Voyer, T. Khan, J. Li, J. Fellay, L. Roussel, M. Shahrooei, M.F.  
796 Alosaimi, D. Mansouri, H. Al-Saud, F. Al-Mulla, F. Almourfi, S.Z. Al-Muhsen, F. Alsohime, S.A. Turki,  
797 R. Hasanato, D. van de Beek, A. Biondi, L.R. Bettini, M. D'Angio', P. Bonfanti, L. Imberti, A. Sottini, S.  
798 Paghera, E. Quiros-Roldan, C. Rossi, A.J. Oler, M.F. Tompkins, C. Alba, I. Vandernoot, J.-C. Goffard,  
799 G. Smits, I. Migeotte, F. Haerynck, P. Soler-Palacin, A. Martin-Nalda, R. Colobran, P.-E. Morange, S.  
800 Keles, F. Çölkesen, T. Ozcelik, K.K. Yasar, S. Senoglu, Ş.N. Karabela, C. Rodríguez-Gallego, G. Novelli,  
801 S. Hraiech, Y. Tandjaoui-Lambiotte, X. Duval, C. Laouénan, C.-S. Clinicians†, C. Clinicians†, et al.  
802 2020. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science*. 370.  
803 doi:10.1126/science.abd4570.

804

## 805 Figure Legends

806

### 807 Figure 1: Low-level chronic DNA damage in SAMHD1-deficient mice

808 (A) Gene set enrichment analysis against the Reactome gene set collection (MSigDB) showing that  
809 exclusively gene sets of immune pathways (blue) and DNA replication (red) are enriched in *Samhd1*<sup>Δ/Δ</sup>  
810 vs. *Samhd1*<sup>+/+</sup> peritoneal macrophages. (B) Corrected total nuclear fluorescence (CTNF) of the  $\gamma$ H2AX  
811 signal in pre-senescent primary MEFs of the indicated genotypes (Student's t test) and representative  
812 immunofluorescence pictures. 10 Gy = positive control, analyzed 60 min after irradiation. (C) Change  
813 in micronucleated reticulocytes (MN-Ret) before (-) and 48 hrs after (+) whole body gamma-  
814 irradiation with a dose of 2 Gy in *Samhd1*<sup>+/+</sup> (n=8) and *Samhd1*<sup>Δ/Δ</sup> (n=5) mice. Fold change compared  
815 to mean of *Samhd1*<sup>+/+</sup> before irradiation is shown (One-way ANOVA followed by Tukey's multiple  
816 comparison test). (D) Relative change in micronucleated normochromatic erythrocytes (MN-NCE)  
817 from peripheral blood of mice with the indicated genotypes. Fold change was calculated for each  
818 genetic background between *Samhd1*<sup>+/+</sup> (+) and *Samhd1*<sup>Δ/Δ</sup> ( $\Delta$ ). For *Mavs* and *Sting1*: + = WT/WT, - =  
819 KO/KO, n $\geq$ 4 for each group (Student's t test). \* = p < 0.05, \*\*\* = p < 0.001, \*\*\*\* = p < 0.0001.

820

### 821 Figure 2: SAMHD1 prevents spontaneous DNA double strand breaks and accelerated 822 transformation in of p53-deficient mice

823 (A) Tumor-free survival of *Samhd1*<sup>+/+</sup>*Trp53*<sup>-/-</sup> (n=15) and  
824 *Samhd1*<sup>Δ/Δ</sup>*Trp53*<sup>-/-</sup> (n=12) mice (log-rank test). For (B & C) + = WT/WT, - =  $\Delta/\Delta$  (B) Relative thymus  
825 weight of mice with the indicated genotypes at 12 weeks of age, n $\geq$ 5 per group (One-way ANOVA  
826 followed by Sidak's multiple comparison test). (C) Thymi of 12 weeks old mice with the indicated  
827 genotypes were examined for lymphoma formation by a trained histopathologist. Numbers of  
828 analyzed thymi in each group are shown and categorized according to the disease state. (D)  
829 Representative sections of a normal *Samhd1*<sup>Δ/Δ</sup>*Trp53*<sup>+/+</sup> (upper) and a *Samhd1*<sup>Δ/Δ</sup>*Trp53*<sup>-/-</sup> lymphoma  
830 bearing thymus. Sections were stained with H&E. (E) Representative multicolor  
831 immunohistochemistry staining for T cell lineage markers of thymic sections from mice with the  
832 indicated genotypes. See also Figure S1. (F) Cell counts of CD4<sup>+</sup>CD8<sup>-</sup>CD44<sup>+</sup>CD25<sup>-</sup> DN1 immature T  
833 cells over time in the thymus of mice with the indicated genotypes. Complete dataset of T cell  
834 development in Figure S2, n $\geq$ 3 for each group and time point (Two-way ANOVA followed by Tukey's  
835 multiple comparison test). (G) Survival of *Samhd1*<sup>Δ/Δ</sup>*Trp53*<sup>-/-</sup> (n=3) and of *Samhd1*<sup>+/+</sup>*Trp53*<sup>-/-</sup> (n=3)  
836 immortalized thymic fibroblasts after treatment with deoxy guanosin (dG) at the indicated  
837 concentrations for 48 h. Representative of two independent experiments is shown (Two-way  
838 ANOVA). (H) Tumor-free survival of *Samhd1*<sup>Δ/Δ</sup>*Pms2*<sup>-/-</sup> (n=51) and of *Samhd1*<sup>+/+</sup>*Pms2*<sup>-/-</sup> mice (n=20). (I)  
839 Frequency of micronucleated normochromatic erythrocytes (MN-NCE) in peripheral blood of  
840 *Samhd1*<sup>Δ/Δ</sup>*Trp53*<sup>-/-</sup> (n=9) and of *Samhd1*<sup>+/+</sup>*Trp53*<sup>-/-</sup> (n=9) (Student's t test). (J) Corrected total nuclear  
841 fluorescence (CTNF) of the  $\gamma$ H2AX signal in pre-senescent primary MEFs from *Samhd1*<sup>Δ/Δ</sup>*Trp53*<sup>-/-</sup> and  
842 *Samhd1*<sup>+/+</sup>*Trp53*<sup>-/-</sup> mice. Representative result of two independent experiments is shown (Student's t  
843 test). (K) Telomere integrity was quantified by FISH in 20 metaphases of immortalized thymic  
844 fibroblasts from *Samhd1*<sup>Δ/Δ</sup>*Trp53*<sup>-/-</sup> and from *Samhd1*<sup>+/+</sup>*Trp53*<sup>-/-</sup> mice (Student's t test).  
845 \*\*\* = p < 0.001, \*\*\*\* = p < 0.0001.

846

### 847 Figure 3: Redundant role of STING signaling in controlling tumor growth and IFN production in 848 *Samhd1*<sup>Δ/Δ</sup>*Trp53*<sup>-/-</sup> compared with *Samhd1*<sup>+/+</sup>*Trp53*<sup>-/-</sup> mice.

849 (A) Tumor-free survival of *Samhd1*<sup>Δ/Δ</sup>*Trp53*<sup>-/-</sup> on a STING-deficient (*Sting1*<sup>GT/GT</sup>) and STING-proficient (*Sting1*<sup>+/+</sup>) genetic  
850 background (log-rank test). (B) Frequency of DAPI<sup>+</sup>Sca-1<sup>+</sup>CD3<sup>+</sup> T cells (left) and DAPI<sup>+</sup>Sca-1<sup>+</sup>CD19<sup>+</sup> B  
851 cells (right) in peripheral blood of mice with the indicated genotypes (One-way ANOVA followed by  
852 Tukey's multiple comparison test). (C – E). Relative transcript levels of ISGs in peripheral blood (C and  
853 E) and BMDMs (D) of mice with the indicated genotypes. Fold change compared to the mean of  
854 *Samhd1*<sup>+/+</sup>*Trp53*<sup>+/+</sup> (C and D) or *Samhd1*<sup>+/+</sup>*Pms2*<sup>+/+</sup> (E) are shown, n=3 for each group in each experiment  
855 (multiple t tests were performed).

\* = p < 0.05, \*\* = p < 0.01, \*\*\* = p < 0.001, n.s. = not significant.

856 **Figure 4: MDA5 drives spontaneous IFN production in a cGAS/STING-dependent manner in**  
857 ***Samhd1*<sup>ΔΔ</sup> mice.** For the whole figure - = homozygous null, + = homozygous wild type. (A) Enrichment  
858 of Reactome gene sets (MSigDB) in the transcriptome of peritoneal macrophages from mutant mice  
859 compared with littermate wild type controls of *Samhd1*<sup>ΔΔ</sup> mice. (B) Normalized read counts for the  
860 indicated ISG transcripts (left) and transcripts of the CELL CYCLE CHECKPOINTS gene set (right)  
861 from the analysis shown in (A). (C) Relative transcript levels of the indicated ISGs measured by qRT-  
862 PCR in post-replicative senescence *Samhd1*<sup>ΔΔ</sup> MEFs with additional CRISPR-mediated inactivation  
863 of the genes *cGas* (n=4), *Ifih1* (n=3) and *Ddx58* (n=2). Data of two independent experiments were  
864 pooled and displayed as fold change compared to the mean of *Samhd1*<sup>+/+</sup> MEFs (multiple t tests,  
865 summary of results is shown with p<0.05 as lowest significance level). (D) Enrichment of Reactome  
866 gene sets (MSigDB) in the transcriptome of peritoneal macrophages from *Samhd1*<sup>ΔΔ</sup>*Ifih1*<sup>+/+</sup>,  
867 *Samhd1*<sup>+/+</sup>*Ifih1*<sup>-/-</sup> and *Samhd1*<sup>ΔΔ</sup>*Ifih1*<sup>-/-</sup> compared with littermate *Samhd1*<sup>+/+</sup>*Ifih1*<sup>+/+</sup> control mice. (E)  
868 Normalized read counts for the indicated ISG transcripts from the experiment shown in (D). (F)  
869 Normalized read counts for transcripts of pattern recognition receptors (PRRs) in BMDMs from  
870 *Samhd1*<sup>ΔΔ</sup>*GFP-cGas*<sup>KI/KI</sup> (n=2) vs. *Samhd1*<sup>+/+</sup> (n=3) control mice and the enrichment plot for the gene  
871 set INTERFERON\_ALPHA\_RESPONSE of the Hallmark gene set (MSigDB). (G) Relative ISG-luciferase  
872 reporter activity in cGAS-competent (WT) and cGAS-deficient (cGas KO) LL171 cells 16 hours after  
873 lipofection with 100 ng/μl poly I:C and 1 μg/ml plasmid DNA (3 kb). Luciferase activity was normalized  
874 to the mean of Lipo-treated WT LL171 cells (Student's t test). (H) BMDMs isolated from *cGas*<sup>+/+</sup> (WT)  
875 and *cGas*<sup>-/-</sup> (cGas KO) mice lipofected with 10 μg/ml plasmid DNA and the indicated amounts of  
876 pppRNA or incubated with 10 μg/ml DMXAA for 4 hours. Cells were washed and incubated for another  
877 18 hours before type I IFN bioactivity in the supernatant was determined using LL171 ISG-LUC  
878 reporter cells (two-way ANOVA). \* = p<0.05, \*\* = p<0.01, \*\*\* = p<0.001.  
879

880 **Figure S1: Characterization of T cell lineage marker expression by multicolor**  
881 **immunofluorescence in thymi of mice with the indicated genotypes.** Related to Figure 2E.  
882

883 **Figure S2: Aberrant T cell development in *Samhd1*<sup>ΔΔ</sup>*Trp53*<sup>-/-</sup> and in *Samhd1*<sup>+/+</sup>*Trp53*<sup>-/-</sup> mice.** Related  
884 to Figure 2. (A) Thymus parameters recorded by flow cytometry. Cells were gated based on scatter to  
885 exclude debris and DAPI- for living cells, before gating on the respective markers. DP = CD4<sup>+</sup>CD8<sup>+</sup>,  
886 DN = CD4<sup>-</sup>CD8<sup>-</sup>, DN1 = CD4<sup>-</sup>CD8<sup>-</sup>CD44<sup>+</sup>CD25<sup>-</sup> (shown in Figure 2F), DN2 = CD4<sup>-</sup>CD8<sup>-</sup>CD44<sup>+</sup>CD25<sup>+</sup>, DN3 =  
887 CD4<sup>-</sup>CD8<sup>-</sup>CD44<sup>-</sup>CD25<sup>+</sup>, DN4 = CD4<sup>-</sup>CD8<sup>-</sup>CD44<sup>-</sup>CD25<sup>-</sup> (Two-way ANOVA followed by Tukey's multiple  
888 comparison test). (B) DNA was extracted from total thymus of mice with the indicated genotypes.  
889 TCRβ loci were amplified by PCR using a combination of 22 primers binding in a V segment combined  
890 with one primer binding in J1.7. Similar results were obtained with primer J2.7 (not shown). Strategy  
891 according to (Martins et al., 2014). \* = p<0.05, \*\* = p<0.001, \*\*\* = p<0.001, \*\*\*\* = p<0.0001.  
892

893 **Figure S3: MDA5 drives spontaneous IFN production in a cGAS/STING-dependent manner in**  
894 ***Samhd1*<sup>ΔΔ</sup> mice.** Related to Figure 4. (A) *Samhd1*<sup>+/+</sup> and *Samhd1*<sup>ΔΔ</sup> mice were treated i.p. with 10  
895 mg/kg/day H-151 or vehicle for 14 days. Transcript levels of the indicated ISGs were determined in  
896 spleen. Fold change compared with the WT-vehicle group is shown, n=4 in each group (Two-way  
897 ANOVA followed by Tukey's multiple comparison test). (B) Post-replicative senescence *Samhd1*<sup>ΔΔ</sup>  
898 and *Samhd1*<sup>+/+</sup> MEFs were transduced with empty lentivirus or a lentivirus which expresses the cDNA  
899 of murine *Samhd1* isoform1 as well as EYFP. Transduced cells were enriched by FACS for EYFP and  
900 transcript levels of the indicated ISGs were determined by qRT-PCR. Data of two independent  
901 measurements is displayed as fold change compared with the mean of *Samhd1*<sup>+/+</sup> MEFs transduced  
902 with empty lentivirus (Two-way ANOVA followed by Tukey's multiple comparison test). (C) Relative  
903 transcript levels of the indicated ISGs measured by qRT-PCR in post-replicative senescence *Samhd1*<sup>ΔΔ</sup>  
904 MEFs with additional CRISPR-mediated inactivation of the genes *cGas* (n=4), *Ifih1* (n=3) and *Ddx58*  
905 (n=2) after lipofection with 1 μg/ml plasmid DNA (dsDNA), 100 ng/ml poly I:C, 100 ng/ml pppRNA or  
906 incubation with 10 μg/ml DMXAA for 16 hours. Fold change compared to Lipo-treated *Samhd1*<sup>+/+</sup>  
907 MEFs is shown. (D) Representative western blot for cGAS in *GFP-cGas*<sup>KI/KI</sup> and *GFP-cGas*<sup>WT/WT</sup> control

908 mice (left). Data from two independent experiments for densitometric quantification of cGAS signal  
909 relative to the signal for  $\beta$ -actin (right, Student's t test). cGAS = 62 kDa, GFP-cGAS around 92 kDa. (E)  
910 Spontaneous *in vivo* Irfnb1-luciferase signal in *Samhd1*<sup>+/ $\Delta$</sup>  (ctrl), *Samhd1* <sup>$\Delta$ / $\Delta$</sup>  and *Trex1*<sup>KO/KO</sup> mice. All mice  
911 were homozygous for the luciferase knock in ( $\Delta\beta$ LUC<sup>KI/KI</sup>). (F) Normalized read counts of ISG  
912 transcripts in *Samhd1* <sup>$\Delta$ / $\Delta$</sup> *Irfh1*<sup>-/-</sup> vs. *Samhd1* <sup>$\Delta$ / $\Delta$</sup> *Sting1*<sup>GT/GT</sup> mice.  
913 \*\*=p<0.01, \*\*\*\*=p<0.0001.















